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IDENTIFICATION OF EBSULFUR 
ANALOGUES WITH BROAD-SPECTRUM 
ANTIFUNGAL ACTIVITY 
FIELD OF THE INVENTION 
The invention relates to small molecule compounds and 
pharmaceutically acceptable salts thereof that are useful, 
among other functions, as anti-fungal agents. The invention 
also relates to the use of these compounds and pharmaceu-
tical compositions in the treatment of patients or crops with 
fungal infections. 
BACKGROUND OF THE INVENTION 
Fungal infections have become an emerging public health 
threat, heightened due to the increasing size of an immuno-
compromised patient population (Arendrup, M. C. (2010) 
Epidemiology of invasive candidiasis. Curr. Opin. Crit. 
Care 16, 445-452). This population includes patients with 
AIDS, primary immune deficiency, and those who are 
immunocompromised due to chemotherapy or organ and 
bone marrow transplantation. 
2 
powerful probe for biochemical studies of the membrane. 
Angew. Chem. 43, 5181-5185; Baginski, M. and Czub, J. 
(2009) Amphotericin B and its new derivatives-mode of 
action. Curr. Drug Metab. 10,459-469; Morris, M. I. and 
5 Villmann, M. (2006) Echinocandins in the management of 
invasive fungal infections, part 1. Am. J. Health Syst. 
Pharm. 63, 1693-1703). 
Due to improper usage of these antifungal agents, such as 
insufficient dosages and durations of treatment, more drug-
IO resistant fungal strains have evolved (Sanguinetti, M. et al. 
(2015) Antifungal drug resistance among Candida species: 
mechanisms and clinical impact. Mycoses 58 Suppl 2, 2-13.; 
Kanafani, Z. A. and Perfect, J. R. (2008) Antimicrobial 
15 resistance: resistance to antifungal agents: mechanisms and 
clinical impact. Clin. Infect. Dis. 46, 120-128; Shah, D. N. 
et al. (2012) Impact of prior inappropriate fluconazole 
dosing isolation offluconazole-nonsusceptible Candida spe-
cies in hospitalized patients with candidemia. Antimicrob. 
20 Agents Chemother. 56, 3239-3243). Additionally, new evi-
dence suggests that antibacterials also contribute to the 
development of fungal resistance. (Ben-Ami, R.et al. (2012) 
Antibiotic exposure as a risk factor for fluconazole-resistant 
Candida bloodstream infection. Antimicrob. Agents Globally, Candida species are the predominant cause of 
invasive systemic fungal infections, with a reported preva-
lence at 6.9 cases per 1000 patients (Kett, D. H. et al. (2011) 
Extended prevalence of infection in ICU study (EPIC II) 
group of investigators Candida bloodstream infections in 
intensive care units: analysis of the extended prevalence of 
infection in intensive care unit study. Crit. Care Med. 39, 
665-670). In the United States, Candida infections rank 
fourth among all hospital-acquired systemic infections in 
intensive care units (Wisplinghoff, H. et al. (2004) Nosoco-
mial bloodstream infections in US hospitals: analysis of 
24,179 cases from a prospective nationwide surveillance 
study. Clin. Infect. Dis. 39, 309-317). In most population-
based studies, Candida infections represent the seventh to 
tenth most common bloodstream infections (Kullberg, B. J. 
andArendrup, M. C. (2015) Invasive candidiasis. N. Engl. J. 
Med. 373, 1445-1456). Additionally, many patients are now 40 
infected with other fungal species, including Aspergillus 
fumigatus, Aspergillus nidulans, and Cryptococcus neofor-
mans (Mayr,A. and Lass-Flori, C. (2011) Epidemiology and 
antifungal resistance in invasive aspergillosis according to 
primary disease: review of the literature. Eur. J. Med. Res. 
25 Chemother. 56, 2518-2523). 
Currently, three strategies have been employed to over-
come antifungal drug resistance. The first strategy is the 
development of compounds with novel mechanisms of 
action distinct from previous antifungal agents. For instance, 
30 compound E1210 was discovered as a novel first-in-class 
antifungal compound by the Tsukuba Research Laboratories 
of Eisai Co., Ltd. This compound was discovered to inhibit 
fungal glycosylphosphatidylinositol (GPI) biosynthesis and 
35 validated in murine models of candidiasis, aspergillosis, and 
fusariosis (Hata, K. et al. (2011) Efficacy of oral E1210, a 
new broad-spectrum antifungal with a novel mechanism of 
action, in murine models of candidiasis, aspergillosis, and 
fusariosis. Antimicrob. Agents Chemother. 55, 4543-4551). 
The second strategy is the combination of two antifungal 
agents. In the literature, there are many examples using two 
compounds in conjunction to produce synergistic antifungal 
activity and reduce resistance as well as toxicity (Kontoyi-
annis, D. P. and Lewis, R. E. (2004) Toward more effective 
45 antifungal therapy: the prospects of combination therapy. Br. 
16, 153-157; van der Linden, J. W. et al., (2015) Prospective 
multicenter international surveillance of azole resistance in 
Aspergillus fumigatus. Emerg. Infect. Dis. 21, 1041-1044; 
Sloan, D. J. and Parris, V. (2014) Cryptococcal meningitis: 
epidemiology and therapeutic options. Clin. Epidemiol. 6, 
169-182). 
Common therapeutic agents used to treat fungal infections 
include azoles ( e.g., fluconazole (FLC), itraconazole (ITC), 
posaconazole (POS), and voriconazole (VOR)), polyenes 
(e.g., amphotericin B (AmB), nystatin (NYS), and candici-
din (CAN)), allylamines (e.g., butenafine, naftifine, and 
terbinafine), and echinocandins (e.g., micafungin, caspo-
fungin, and anidulafungin). These drugs function by differ-
ent mechanisms of action: (i) inhibition of the cytochrome 
P450 enzyme 14a-demethylase (azoles); (ii) introduction of 
transmembrane channel leading to monovalent ion leakage 
(polyenes); (iii) inhibition of squalene epoxidase (allylam-
ines); and (iv) inhibition of synthesis of glucan in the fungal 
cell wall via the enzyme 1,3-~-glucan synthase ( echinochan-
dins) (Pasko, M. T. et al. (1990) Fluconazole: a new triazole 
antifungal agent. DICP 1990, 24, 860-867; Zumbuehl, A.et 
al. (2004) An amphotericin B-fluorescein conjugate as a 
J. Haematol. 126, 165-175; Day, J. N. et al. (2013) Com-
bination antifungal therapy for cryptococcal meningitis. N. 
Engl. J. Med. 368, 1291-1302). Specifically, in patients 
diagnosed with cryptococcal meningitis, the combination 
50 therapy of flucytosine and AmB was shown to be essential 
for successful clinical outcomes (Perfect, J. R. et al. (2010) 
Clinical practice guidelines for the management of crypto-
coccal disease: 2010 update by the Infectious Diseases 
55 
Society of America. Clin. Infect. Dis. 50, 291-322). 
Recently, it was also found that a combination of azoles and 
analogues of the aminoglycoside antibiotics tobramycin and 
kanamycin B resulted in favorable synergistic effects against 
drug-resistant Candida albicans strains (Shrestha, S. K., et 
60 al. (2015) A combination approach to treating fungal infec-
tions. Sci. Rep. 5, 17070; Fosso, M. Y. et al. (2015) Synthesis 
and bioactivities of kanamycin B-derived cationic amphi-
philes. J. Med. Chem. 58, 9124- 9132). 
The third strategy is the use of known compounds for new 
65 applications. For example, the decongestant drug octodrine 
was identified as a broad-spectrum antifungal compound. 
Kim, K. et al. (2015) Repurposing FDA approved drugs 
US 10,544,112 B2 
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against the human fungal pathogen, Candida albicans. Ann. 
Clin. Microbial. Antimicrob. 14, 32. 
4 
major healthcare problem. Thus, there is a critical need for 
the development of novel antifungal compounds. 
BRIEF SUMMARY OF THE INVENTION 
The invention is directed to novel ebselen and ebsulfur 
analogues and novel pharmaceutical compositions compris-
ing ebselen and ebsulfur analogues of formula (I). The 
invention is also directed to novel methods of treating 
infections caused by fungal species comprising administra-
tion of ebselen, ebsulfur, ebselen analogues, and ebsulfur 
analogues of formula (I). 
The invention employs two strategies to overcome anti-
fungal drug resistance: (1) the use of known compounds 
5 previously unknown to have anti-fungal activity; and (2) the 
development of new anti-fungal compounds. 
Ebselen is an organoseleno compound, which has com-
pleted phase I clinical trial for general safety in human use. 
Ebselen has diverse therapeutic applications and has been 
10 studied in several clinical trials. (Azad, G. K. and Tamar, R. 
S. (2014) Ebselen, a promising antioxidant drug: mecha-
nisms of action and targets of biological pathways. Mal. 
Biol. Rep. 41, 4865-4879). Ebselen is currently in phase 2 
(I) clinical trials for the treatment of chemotherapy-induced 
15 hearing loss and Meniere' s disease (http://clinicaltrials.gov). 
R, ~y(_R l_jJ--> y X 
Furthermore, ebselen completed a 300-patient phase 3 clini-
cal trial for cerebral ischemia in Japan (Parnham, M. J. and 
Sies, H. (2013) The early research and development of 
ebselen. Biochem. Pharmacol. 86, 1248-1253). It has been 
20 surprisingly discovered that ebselen also exhibits anti-fungal 
activity. 
BRIEF DESCRIPTION OF THE DRAWINGS 
In addition, the ebsulfur, or 1,2-benzisothiazol-3(2H)-
one, scaffold has been shown to exhibit a narrow spectrum 
of antibacterial activity, i.e., it exhibits activity only against FIG. lA. Time-kill analysis of ebselen (1) (black inverted 
triangles), ebsulfur (2a) (white triangles), compound 3a 
(black squares) was performed at 0, 3, 6, 9, 12, and 24 h. 
Cultures were exposed to compounds at 1 xtheir respective 
MIC values. Untreated culture (black circles) was used as 
the negative control and AmB (white circles) was used the 
positive control. 
25 methicillin-resistant Staphylococcus aureus (MRSA) (Ngo, 
H. X. et al. (2016) Development of ebsulfur analogues as 
potent antibacterials against methicillin-resistant Staphylo-
coccus aureus. Bioorg. Med. Chem. doi: 10.1016/ 
j.bmc.2016.03.060). It has also been surprisingly discovered 
30 that the ebsulfur scaffold also exhibits anti-fungal activity. 
Further, due to the structural similarities between ebsulfur 
and ebselen, it was hypothesized that ebsulfur and its 
analogues would have a safety profile comparable to that of 
ebselen. Accordingly, new ebsulfur analogues were prepared 
FIG. 18. Time-kill analysis of ebselen (1) (black inverted 
triangles), ebsulfur (2a) (white triangles), compound 3a 
(black squares) was performed at 0, 3, 6, 9, 12, and 24 h. 
Cultures were exposed to compounds at 2x their respective 
MIC values. Untreated culture (black circles) was used as 
the negative control and AmB (white circles) was used the 
positive control. 
35 for the treatment of fungal infections. 
FIG. lC. Time-kill analysis of ebselen (1) (black inverted 
triangles), ebsulfur (2a) (white triangles), compound 3a 
(black squares) was performed at 0, 3, 6, 9, 12, and 24 h. 40 
Cultures were exposed to compounds at 4x their respective 
MIC values. Untreated culture (black circles) was used as 
the negative control and AmB (white circles) was used the 
positive control. 
FIG. 2A. Mammalian cell cytotoxicity of ebselen (1) 
(black bars), and compounds 3a (white bars), 3b (gray bars), 45 
and 3g (bars with dashes) was determined against HEK 293 
cell line. Triton-X 100® (1 %, v/v) was used as the positive 
control (data not shown). 
FIG. 2B. Mammalian cell cytotoxicity of ebselen (1) 
(black bars), and compounds 3a (white bars), 3b (gray bars), 50 
and 3g (bars with dashes) was determined against 1774 cell 
line. Triton-X 100® (1 %, v/v) was used as the positive 
control (data not shown). 
The invention may be understood more readily by refer-
ence to the following detailed description of exemplary 
embodiments of the invention and the examples included 
therein. It is to be understood that this invention is not 
limited to specific methods of synthesis, which may of 
course vary. It is also to be understood that the terminology 
used herein is for the purpose of describing particular 
embodiments only and is not intended to be limiting. 
As used herein, the term "aryl" refers to aromatic groups 
having 6 to 24 carbon atoms, and "substituted aryl" refers to 
aryl groups further bearing one or more substituents. 
The term "heteroaryl" refers to aromatic groups having 4 
to 23 carbon atoms and at least one or more element selected 
from the group consisting of nitrogen, oxygen, and sulfur; 
"substituted heteroaryl" refers to heteroaryl groups further 
bearing one or more substituents. 
The term "alkyl" refers to straight or branched chain alkyl 
radicals having 1 to 20 carbon atoms, and "substituted alkyl" 
refers to alkyl radicals further bearing one or more substitu-FIG. 3. ROS induction assay of ebselen (1 ), ebsulfur (2a), 
and compound 3a was performed against C. albicans ATCC 
10231 (strain A). Candida cells were treated with no drug 
(negative control), 1 mM of H20 2 (positive control), or 
ebselen, 2a, and 3a at their 1 x and 2x respective MIC values 
55 ents. 
for 1 h at 3 7° C. DCFH-DA ( 40 µg/mL) was added to detect 
ROS and the samples were analyzed using a Zeiss Axovert 60 
200M fluorescence microscope. 
The term "lower alkyl" refers to straight or branched 
chain alkyl radicals having in the range of 1 to 4 carbon 
atoms. 
The term "cycloalkyl" refers to cyclic ring-containing 
moieties containing 3 to 20 carbon atoms, and "substituted 
cycloalkyl" refers to cycloalkyl moieties further bearing one 
or more substituents. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The term "pharmaceutically acceptable" refers to a non-
toxic material that does not interfere with the effectiveness 
65 of the active ingredient(s). 
Overall, fungal resistance is still relatively uncommon, 
but this problem is on the rise and expected to become a 
The term "therapeutically effective amount" means an 
amount of a compound of the invention that (i) treats or 
US 10,544,112 B2 
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prevents the particular disease, condition, or disorder, (ii) 
attenuates, ameliorates, or eliminates one or more symptoms 
of the particular disease, condition, or disorder, or (iii) 
prevents or delays the onset of one or more symptoms of the 
particular disease, condition, or disorder described herein. 
Substituted aryl groups, substituted heteroaryl groups, 
substituted alkyl groups, and substituted cycloalkyl groups 
are substituted with one or more substituents selected from 
the group consisting of C1 -C6 alkyl, -ORa, -SRb, 
-NRcRd, -F, --Cl, -Br, -I, ----CN, -NO2 , phenyl, 
pyridyl, -CHO, --COO Re, -CO(NR_.,Rg); wherein each of 
Ra, Rb, Re, Rd., Re, Rfi and Rg are independently selected 
from H or C1 -C6 alkyl. 
Salts are acid addition salts, including c1-, Br, 1-, NO2 -, 
HSO4-, SO4 -, HPO4-, Po/-, ethanesulfonate, triflurometh-
ane sulfate, p-toluenesulfonate, benzenesulfonate, salicy-
late, propionate, ascorbate, aspartate, fumarate, galactarate, 
maleate, citrate, glutamate, glycolate, lactate, malate, 
maleate, tartrate, oxalate, succinate, and the like. 
Where a salt is intended to be administered to a patient (as 
opposed to, for example, being used in an in vitro context), 
the salt preferably is pharmaceutically acceptable. The term 
"pharmaceutically acceptable salt" refers to a salt prepared 
by combining a compound of Formula I with an acid whose 
anion, or a base whose cation, is generally considered 
suitable for human consumption. Pharmaceutically accept-
able salts are particularly useful as products of the methods 
of the invention because of their greater aqueous solubility 
relative to the parent compound. For use in medicine, the 
salts of the compounds of this invention are non-toxic 
"pharmaceutically acceptable salts." Salts encompassed 
within the term "pharmaceutically acceptable salts" refer to 
non-toxic salts of the compounds of this invention which are 
generally prepared by reacting the free base with a suitable 
organic or inorganic acid. 
As used herein, the term "Formula (I)" may be hereinafter 
referred to as a "compound(s) of the invention," "the inven-
tion," and "compound of Formula I." Such terms are also 
defined to include all forms of the compound of Formula I, 
including hydrates, solvates, isomers, crystalline and non-
crystalline forms, isomorphs, polymorphs, and metabolites 
thereof. For example, the compounds of the invention, or 
pharmaceutically acceptable salts thereof, may exist in 
unsolvated and solvated forms. When the solvent or water is 
tightly bound, the complex will have a well-defined stoichi-
ometry independent of humidity. When, however, the sol-
vent or water is weakly bound, as in channel solvates and 
hygroscopic compounds, the water/solvent content will be 
dependent on humidity and drying conditions. In such cases, 
non-stoichiometry will be the norm. 
The invention provides compounds of formula (I): 
6 
R1 may be-H, -OH, -NH2 , ORb, CF3 , NO2 , or CN; 
Ra may be linear or branched C1_16 alkyl groups or linear 
pegylated C4 _16 alkyl groups; and 
Rb may be linear or branched C1_16 alkyl groups; 
or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is Se; Y is C; R1 is -H, and R is 
substituted or unsubstituted aryl, substituted or unsubstituted 
heteroaryl, substituted or unsubstituted alkyl, or substituted 
10 
or unsubstituted cycloalkyl; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is Se; Y is C; R1 is -H, and R is 
substituted or unsubstituted aryl or substituted or unsubsti-
15 tuted heteroaryl; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is Se; Y is C; R1 is -H, and R is 
substituted or unsubstituted aryl; or a salt thereof. 
A further embodiment of the invention is a compound of 
20 formula (I), wherein: X is Se; Y is C; R1 is -H, and R is a 
substituted or unsubstituted aryl selected from the group 
consisting of substituted or unsubstituted phenyl, substituted 
or unsubstituted naphthalene, substituted or unsubstituted 
anthracene, substituted or unsubstituted phenanthrene, and 
25 substituted or unsubstituted pyrene; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is Se; Y is C; R1 is -H, and R is 
substituted or unsubstituted heteroaryl; or a salt thereof. 
A further embodiment of the invention is a compound of 
30 formula (I), wherein: X is Se; Y is C; R1 is -H, and R is a 
substituted or unsubstituted heteroaryl selected from the 
group consisting of substituted or unsubstituted pyridine, 
substituted or unsubstituted quinoline, substituted or unsub-
35 stituted thiophene, substituted or unsubstituted pyrrole, sub-
stituted or unsubstituted furan, substituted or unsubstituted 
imidazole, substituted or unsubstituted oxazole, and substi-
tuted or unsubstituted thiazole; or a salt thereof. 
A further embodiment of the invention is a compound of 
40 formula (I), wherein: X is Se; Y is C; R1 is -H, and R is 
substituted or unsubstituted alkyl, or substituted or unsub-
stituted cycloalkyl; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is Se; Y is C; R1 is -H, and R is 
45 substituted or unsubstituted alkyl; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is Se; Y is C; R1 is -H, and R is a 
C1 -C20 alkyl that is unsubstituted or substituted with one or 
more substituents selected from the group consisting of 
50 cl -C6 alkyl, -ORa, -SRb, -F, -Cl, -Br, -I, -CN, 
-NO2 , phenyl, pyridyl, -CHO, ----COORe, ----CO(NR_.,Rg); 
wherein each of Ra, Rb, Rd, Re, Rfi and Rg are independently 
selected from H or C1 -C6 alkyl; or a salt thereof. 
R,~N-R l_jl_; 
(I) 55 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is Se; Y is C; R1 is -H, and R is 
selected from the group consisting of substituted or unsub-
stituted butyl, pentyl, hexyl, heptyl, octyl, decyl, and dode-
cyl; or a salt thereof. 
y X 
wherein 
X may be Se, S, or S=O; 
Y may be C, N, or O; 
R may be substituted or unsubstituted aryl, substituted or 
unsubstituted heteroaryl, substituted or unsubstituted 
alkyl, substituted or unsubstituted cycloalkyl, or ORa; 
A further embodiment of the invention is a compound of 
60 formula (I), wherein: X is Se; Y is C; R1 is -H, and R is 
substituted or unsubstituted cycloalkyl; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is Se; Y is C; R1 is -H, and R is a 
monocyclic C3 -C20 alkyl that is unsubstituted or substituted 
65 with one or more substituents selected from the group 
consisting of cl -C6 alkyl, -ORa, -SRb, -F, --Cl, -Br, 
-I, ----CN, -NO2 , phenyl, pyridyl, --CHO, -COORe, 
US 10,544,112 B2 
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-CO(NR?g); wherein each of Ra, Rb, Re, Rd, Re, Rfi and 
Rg are independently selected from H or C1 -C6 alkyl; or a 
salt thereof. 
8 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is C; R1 is -H, and R is 
substituted or unsubstituted alkyl; or a salt thereof. 
A further embodiment of the invention is a compound of A further embodiment of the invention is a compound of 
formula (I), wherein: X is Se; Y is C; R1 is -H, and R is 
selected from the group consisting of substituted or unsub-
stituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 
cycloheptyl, cyclooctyl, cyclodecyl, and cyclododecyl; or a 
salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is Se; Y is C; R1 is -H, and R is a 
bicyclic CcC20 alkyl that is unsubstituted or substituted with 
one or more substituents selected from the group consisting 
5 formula (I), wherein: X is S; Y is C; R1 is -H, and R is a 
C1 -C20 alkyl that is unsubstituted or substituted with one or 
more substituents selected from the group consisting of 
cl -C6 alkyl, ---ORa, -SRb, -NReRd, --Cl, -Br, -I, 
----CN, -NO2 , phenyl, pyridyl, --CHO, -COORe, --CO 10 
of cl -C6 alkyl, ---ORa, -SRb, -F, --Cl, -Br, -I, -CN, 
-NO2 , phenyl, pyridyl, -CHO, -COORe, ----CO(NR?g); 15 
wherein each of Ra, Rb, Re, Rd, Re, Rfi and Rg are indepen-
dently selected from H or C1 -C6 alkyl; or a salt thereof. 
(NR?g); wherein each of Ra, Rb, Rd, Re, Rfi and Rg are 
independently selected from H or C1 -C6 alkyl; or a salt 
thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is C; R1 is -H, and R is 
selected from the group consisting of substituted or unsub-
stituted butyl, pentyl, hexyl, heptyl, octyl, decyl, and dode-
cyl; or a salt thereof. A further embodiment of the invention is a compound of 
formula (I), wherein: X is Se; Y is C; R1 is -H, and R is 
selected from decalin or norbomane; or a salt thereof. 
A further embodiment of the invention is a compound of 
20 formula (I), wherein: X is S; Y is C; R1 is -H, and R is 
substituted or unsubstituted cycloalkyl; or a salt thereof. A further embodiment of the invention is a compound of 
formula (I), wherein: X is Se; Y is C; R1 is -H, and R is a 
tricyclic C3 -C20 alkyl that is unsubstituted or substituted 
with one or more substituents selected from the group 
consisting of cl -C6 alkyl, ---ORa, -SRb, -NReRd, -F, 25 
-Cl, -Br, -I, -CN, -NO2 , phenyl, pyridyl, -CHO, 
-COO Re, ----CO(NR?g); wherein each of Ra, Rb, Re, Rd, 
Re, Rfi and Rg are independently selected from H or C1 -C6 
alkyl; or a salt thereof. 
A further embodiment of the invention is a compound of 30 
formula (I), wherein: X is Se; Y is C; R1 is -H, and R is 
adamantane; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is C; R1 is -H, and R is 
substituted or unsubstituted aryl, substituted or unsubstituted 35 
heteroaryl, substituted or unsubstituted alkyl, or substituted 
or unsubstituted cycloalkyl; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is C; R1 is -H, and R is 
substituted or unsubstituted aryl or substituted or unsubsti- 40 
tuted heteroaryl; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is C; R1 is -H, and R is 
substituted or unsubstituted aryl; or a salt thereof. 
A further embodiment of the invention is a compound of 45 
formula (I), wherein: X is S; Y is C; R1 is -H, and R is a 
substituted or unsubstituted aryl selected from the group 
consisting of substituted or unsubstituted phenyl, substituted 
or unsubstituted naphthalene, substituted or unsubstituted 
anthracene, substituted or unsubstituted phenanthrene, and 50 
substituted or unsubstituted pyrene; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is C; R1 is -H, and R is 
substituted or unsubstituted heteroaryl; or a salt thereof. 
A further embodiment of the invention is a compound of 55 
formula (I), wherein: X is S; Y is C; R1 is -H, and R is a 
substituted or unsubstituted heteroaryl selected from the 
group consisting of substituted or unsubstituted pyridine, 
substituted or unsubstituted quinoline, substituted or unsub-
stituted thiophene, substituted or unsubstituted pyrrole, sub- 60 
stituted or unsubstituted furan, substituted or unsubstituted 
imidazole, substituted or unsubstituted oxazole, and substi-
tuted or unsubstituted thiazole; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is C; R1 is -H, and R is 65 
substituted or unsubstituted alkyl, or substituted or unsub-
stituted cycloalkyl; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is C; R1 is -H, and R is a 
monocyclic C3 -C20 alkyl that is unsubstituted or substituted 
with one or more substituents selected from the group 
consisting of cl -C6 alkyl, ---ORa, -SRb, -NReRd, -F, 
--Cl, -Br, -I, -CN, -NO2 , phenyl, pyridyl, -CHO, 
--COO Re, ----CO(NR?g); wherein each of Ra, Rb, Re, Rd, 
Re, Rfi and Rg are independently selected from H or C1 -C6 
alkyl; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is C; R1 is -H, and R is 
selected from the group consisting of substituted or unsub-
stituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 
cycloheptyl, cyclooctyl, cyclodecyl, and cyclododecyl; or a 
salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is C; R1 is -H, and R is a 
bicyclic CcC20 alkyl that is unsubstituted or substituted with 
one or more substituents selected from the group consisting 
of cl -C6 alkyl, ---ORa, -SRb, -NReRd, -F, --Cl, -Br, 
-I, ----CN, -NO2 , phenyl, pyridyl, --CHO, -COORe, 
----CO(NR?g); wherein each of Ra, Rb, Re, Rd, Re, Rfi and 
Rg are independently selected from H or C1 -C6 alkyl; or a 
salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is C; R1 is -H, and R is 
selected from decalin or norbomane; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is C; R1 is -H, and R is a 
tricyclic C3 -C20 alkyl that is unsubstituted or substituted 
with one or more substituents selected from the group 
consisting of cl -C6 alkyl, -ORa, -SRb, -F, --Cl, -Br, 
-I, ----CN, -NO2 , phenyl, pyridyl, --CHO, -COORe, 
----CO(NR?g); wherein each of Ra, Rb, Re, Rd, Re, Rfi and 
Rg are independently selected from H or C1 -C6 alkyl; or a 
salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is C; R1 is -H, and R is 
adamantane; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S=O; Y is C; R1 is -H, and R 
is substituted or unsubstituted alkyl, or substituted or unsub-
stituted cycloalkyl; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S=O; Y is C; R1 is -H, and R 
is substituted or unsubstituted alkyl; or a salt thereof. 
US 10,544,112 B2 
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A further embodiment of the invention is a compound of 
formula (I), wherein: X is S=O; Y is C; R1 is -H, and R 
is a C1 -C20 alkyl that is unsubstituted or substituted with one 
or more substituents selected from the group consisting of 
cl -C6 alkyl, -ORa, -SRb, -NReRd, -F, --Cl, -Br, -I, 5 
-CN, -NO2 , phenyl, pyridyl, --CHO, -COORe, --CO 
(NR;Rg); wherein each of Ra, Rb, Re, Rd, Re, Rfi and Rg are 
independently selected from H or C1 -C6 alkyl; or a salt 
thereof. 
A further embodiment of the invention is a compound of 10 
formula (I), wherein: X is S=O; Y is C; R1 is -H, and R 
is selected from the group consisting of substituted or 
unsubstituted butyl, pentyl, hexyl, heptyl, octyl, decyl, and 
dodecyl; or a salt thereof. 
A further embodiment of the invention is a compound of 15 
formula (I), wherein: X is S=O; Y is C; R1 is -H, and R 
is substituted or unsubstituted cycloalkyl; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S=O; Y is C; R1 is -H, and R 
is a monocyclic C3 -C20 alkyl that is unsubstituted or sub- 20 
stituted with one or more substituents selected from the 
group consisting of cl -C6 alkyl, ---ORa, -SRb, -NReRd, 
-F, -Cl, -Br, -I, ----CN, -NO2 , phenyl, pyridyl, 
-CHO, -COORe, -CO(NR;Rg); wherein each of Ra, Rb, 
Re, Rd, Re, Rfi and Rg are independently selected from H or 25 
C1 -C6 alkyl; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S=O; Y is C; R1 is -H, and R 
is selected from the group consisting of substituted or 
unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, cyclo- 30 
hexyl, cycloheptyl, cyclooctyl, cyclodecyl, and cyclodode-
cyl; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: 
X=Se; Y=C; R1~H, and 35 
40 
X=Se; Y=C; R1~H, and 
45 
50 
X=Se; Y=C; R1~H, and 
55 
X=Se; Y=C; R1~H, and 
60 
65 
10 
X=Se; Y=C; R1~H, and 
X=Se; Y=C; R1~H, and 
X=Se; Y=C; R1~H, and 
X=Se; Y=C; R1~H, and 
t--Q 
R~ Br; 
X=Se; Y=C; R1~H, and 
X=Se; Y=C; R1~H, and 
Br 
~ 
Br; 
X=Se; Y=C; R1~H, and 
US 10,544,112 B2 
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' 1 -H, and X=Se; Y=C- R _ 12 ' 1 H, and 
10 X=Se· y ' =C-R-' 1 H, and 
X=Se· y ' =C-R-' 1 H, and 
15 
X=Se· y ' =C-R-' 1 H, and 
20 
X=Se· y ' =C-R-' 1 H, and 
X=Se· y ' =C-R-' 1 H, and 
30 
X=Se· y ' =C-R-' 1 -H, and 
35 
J--0-o X=Se· y ' =C-R-' 1 H, and 
40 
X=Se· y ' =C-R-' 1 H, and 
45 
X=Se· y ' =C-R-' 1 H, and 
50 
X=Se· y ' =C-R-' 1 H, and 
55 
X=Se· y ' =C-R-' 1 H, and 
X=Se· y ' =C-R-' 1 H, and 
60 
65 
13 
X=Se; Y=C; R1~H, and 
X=Se; Y=C; R1~H, and 
X=Se; Y=C; R1~H, and 
X=Se; Y=C; R1~H, and 
X=Se; Y=C; R1~H, and 
X=Se; Y=C; R1~H, and 
US 10,544,112 B2 
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X=Se=O; Y=C; R1~H, and or 
10 
15 
A further embodiment of the invention is a compound of 
20 formula (I), wherein: X is S; Y is N; R1 is selected from the 
group consisting of-H, -OH, -NH2, ---OR6 , CF3 , NO2, 
or CN; R is selected from the group consisting of substituted 
alkyl, unsubstituted alkyl, and ORa; Ra is selected from the 
group consisting oflinear C1_16 alkyl groups, branched C1_16 
25 alkyl groups, or linear pegylated C4 _16 alkyl groups; or a salt 
thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is N; R1 is selected from the 
group consisting of -H, -OH, -NH2, ---OMe, ---OEt, 
OPr, OiPr, CF 3 , NO2, or CN; and R is selected from methyl, 30 ethyl, propyl, or isopropyl; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is N; R1 is selected from the 
group consisting of -H, -OH, -NH2, ---OMe, ---OEt, 
OPr, OiPr, CF3 , NO2, or CN; and R is -O----CH2----CH2-
35 O----CH2; or a salt thereof. 
A further embodiment of the invention is a compound of 
formula (I), wherein: X is S; Y is O; R1 is selected from the 
group consisting of-H, -OH, -NH2, ---OR6 , CF3 , NO2, 
or CN; R is selected from the group consisting of substituted 
40 alkyl, unsubstituted alkyl, and ORa; Ra is selected from the 
group consisting oflinear C1_16 alkyl groups, branched C1_16 
alkyl groups, or linear pegylated C4 _16 alkyl groups; or a salt 
thereof. 
A further embodiment of the invention is a compound of 
45 formula (I), wherein: X is S; Y is O; R1 is selected from the 
group consisting of -H, -OH, -NH2, ---OMe, ---OEt, 
OPr, OiPr, CF 3 , NO2, or CN; and R is selected from methyl, 
ethyl, propyl, or isopropyl; or a salt thereof. 
A further embodiment of the invention is a compound of 
50 formula (I), wherein: X is S; Y is O; R1 is selected from the 
group consisting of -H, -OH, -NH2, ---OMe, ---OEt, 
OPr, OiPr, CF3 , NO2, or CN; and R is -O----CH2----CH2-
O----CH2; or a salt thereof. 
Another aspect of the invention is a new pharmaceutical 
55 composition comprising a therapeutically effective amount 
of at least one compound of formula (I) or a salt thereof and 
at least one pharmaceutically acceptable excipient. The 
compounds of the invention may be administered by any 
suitable route, preferably in the form of a pharmaceutical 
60 composition adapted to such a route, and in a dose effective 
for the treatment intended. The active compounds and 
compositions, for example, may be administered orally, 
rectally, parenterally, or topically. 
Oral administration of a solid dose form may be, for 
65 example, presented in discrete units, such as hard or soft 
capsules, pills, cachets, lozenges, or tablets, each containing 
a predetermined amount of at least one compound of the 
US 10,544,112 B2 
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For intranasal administration or administration by inha-
lation, the active compounds of the invention are conve-
niently delivered in the form of a solution or suspension 
from a pump spray container that is squeezed or pumped by 
invention. In another embodiment, the oral administration 
may be in a powder or granule form. In another embodiment, 
the oral dose form is sub-lingual, such as, for example, a 
lozenge. In such solid dosage forms, the compounds of 
Formula I are ordinarily combined with one or more adju-
vants. Such capsules or tablets may contain a controlled-
release formulation. In the case of capsules, tablets, and 
pills, the dosage forms also may comprise buffering agents 
or may be prepared with enteric coatings. 
5 the patient or as an aerosol spray presentation from a 
pressurized container or a nebulizer, with the use of a 
suitable propellant. Formulations suitable for intranasal 
administration are typically administered in the form of a 
dry powder ( either alone, as a mixture, for example, in a dry 
In another embodiment, oral administration may be in a 
liquid dose form. Liquid dosage forms for oral administra-
tion include, for example, pharmaceutically acceptable 
emulsions, solutions, suspensions, syrups, and elixirs con-
taining inert diluents commonly used in the art (e.g., water). 
Such compositions also may comprise adjuvants, such as 
wetting, emulsifying, suspending, flavoring (e.g., sweeten-
ing), and/or perfuming agents. 
10 blend with lactose, or as a mixed component particle, for 
example, mixed with phospholipids, such as phosphatidyl-
choline) from a dry powder inhaler or as an aerosol spray 
from a pressurized container, pump, spray, atomizer (pref-
erably an atomizer using electrohydrodynamics to produce a 
15 fine mist), or nebulizer, with or without the use of a suitable 
propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3, 
3-heptafluoropropane. For intranasal use, the powder may 
comprise a bioadhesive agent, for example, chitosan or 
In another embodiment, the invention comprises a paren-
teral dose form. "Parenteral administration" includes, for 20 
example, subcutaneous injections, intravenous injections, 
intraperitoneal injections, intramuscular injections, intraster-
nal injections, and infusion. Injectable preparations (e.g., 
sterile injectable aqueous or oleaginous suspensions) may be 
formulated according to the known art using suitable dis- 25 
persing, wetting agents, and/or suspending agents. 
In another embodiment, the invention comprises a topical 
dose form. "Topical administration" includes, for example, 
transdermal administration, such as via transdermal patches 
cyclodextrin. 
In another embodiment, the invention comprises a rectal 
dose form. Such rectal dose form may be in the form of, for 
example, a suppository. Cocoa butter is a traditional sup-
pository base, but various alternatives may be used as 
appropriate. 
Other carrier materials and modes of administration 
known in the pharmaceutical art may also be used. Phar-
maceutical compositions of the invention may be prepared 
by any of the well-known techniques of pharmacy, such as 
effective formulation and administration procedures. The 
30 above considerations in regard to effective formulations and 
administration procedures are well known in the art and are 
described in standard textbooks. Formulation of drugs is 
discussed in, for example, Hoover, John E., Remington's 
Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 
or iontophoresis devices, intraocular administration, or 
intranasal or inhalation administration. Compositions for 
topical administration also include, for example, topical 
gels, sprays, ointments, and creams. A topical formulation 
may include a compound which enhances absorption or 
penetration of the active ingredient through the skin or other 
affected areas. When the compounds of this invention are 
administered by a transdermal device, administration will be 
accomplished using a patch either of the reservoir and 
porous membrane type or of a solid matrix variety. Typical 
formulations for this purpose include gels, hydrogels, 40 
lotions, solutions, creams, ointments, dusting powders, 
dressings, foams, films, skin patches, wafers, implants, 
sponges, fibres, bandages and microemulsions. Liposomes 
may also be used. Typical carriers include alcohol, water, 
mineral oil, liquid petrolatum, white petrolatum, glycerin, 45 
polyethylene glycol and propylene glycol. Penetration 
enhancers may be incorporated; see, for example, J. Pharm. 
Sci., 88 (10), 955-958, by Finnin and Morgan (October 
1999). 
35 1975; Liberman et al., Eds., Pharmaceutical Dosage Forms, 
Marcel Decker, New York, N.Y., 1980; and Kibbe et al., 
Eds., Handbook of Pharmaceutical Excipients (3.sup.rd 
Ed.), American Pharmaceutical Association, Washington, 
1999. 
Formulations suitable for topical administration to the eye 50 
include, for example, eye drops wherein the compound of 
this invention is dissolved or suspended in a suitable carrier. 
A typical formulation suitable for ocular or aural adminis-
tration may be in the form of drops of a micronized 
suspension or solution in isotonic, pH-adjusted, sterile 55 
saline. Other formulations suitable for ocular and aural 
The dosage regimen for the compounds and/or composi-
tions containing the compounds is based on a variety of 
factors, including the type, age, weight, sex and medical 
condition of the patient; the severity of the condition; the 
route of administration; and the activity of the particular 
compound employed. Thus the dosage regimen may vary 
widely. Dosage levels of the order from about 0.01 mg to 
about 100 mg per kilogram of body weight per day are 
useful in the treatment of the above-indicated conditions. 
For example, pharmaceutical compounds of formula (I) or 
salts thereof may be present in pharmaceutical compositions 
in an amount of 1 µg to 1000 mg, 1 µg to 1 mg, 1 µg to 500 
1 µg to 250 or 1 µg to 100 µg. Pharmaceutical compounds 
of formula (I) or salts thereof may also be present in 
pharmaceutical compositions in an amount of 1 mg to 1000 
mg, 1 mg to 500 mg, 1 mg to 250 mg, 1 mg to 100 mg, . 
In many instances, the administration of the compound 
will be repeated a plurality of times in a day. Multiple doses 
per day typically may be used to increase the total daily 
dose, if desired. 
Another aspect of the invention is a new pharmaceutical 
composition comprising a therapeutically effective amount 
of at least one compound of formula (I) or a salt thereof and 
at least one pharmaceutically acceptable excipient, wherein 
the pharmaceutical composition is administered once per 
administration include ointments, biodegradable ( e.g., 
absorbable gel sponges, collagen) and non-biodegradable 
(e.g., silicone) implants, wafers, lenses and particulate or 
vesicular systems, such as niosomes or liposomes. A poly- 60 
mer such as cross-linked polyacrylic acid, polyvinyl alcohol, 
hyaluronic acid, a cellulosic polymer, for example, hydroxy-
propylmethyl cellulose, hydroxyethyl cellulose, or methyl 
cellulose, or a heteropolysaccharide polymer, for example, 
gelan gum, may be incorporated together with a preserva-
tive, such as benzalkonium chloride. Such formulations may 
also be delivered by iontophoresis. 
65 day, twice per day, or three times per day. 
A further embodiment of the invention is a new pharma-
ceutical composition comprising a therapeutically effective 
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amount of at least one compound of formula (I) or a salt 
thereof and at least one pharmaceutically acceptable excipi-
ent, wherein the pharmaceutical composition is in the form 
18 
include fish ( e.g., zebrafish), amphibians ( e.g., Xenopus 
laevis and Xenopus tropicalis), and mammals. 
In one embodiment of the invention, subject in need of 
treatment of an infection caused by a fungal species with a of a solution, suspension, gel, emulsion, solid, or powder. 
Any of these forms may be used for oral administration, 
topical administration, or parenteral administration, intrana-
sal administration, or rectal administration. 
Another aspect of the invention is a new agricultural 
composition comprising a therapeutically effective amount 
5 therapeutically effective amount of a compound of formula 
(I) may be a mammal. Examples of mammals that may be 
treated according to the invention include humans, primates, 
horses, sheep, pigs, cows, mice, rats, rabbits, dogs, and cats. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is Se; Y is C; R1 is -H, and R is substituted or unsubstituted 
aryl, substituted or unsubstituted heteroaryl, substituted or 
unsubstituted alkyl, or substituted or unsubstituted 
cycloalkyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
of at least one compound of formula (I) or a salt thereof and 10 
at least one agriculturally acceptable excipient. The com-
pounds of the invention may be administered by any suitable 
route, preferably in the form of an agricultural composition 
adapted to such a route, and in a dose effective for the 15 
treatment intended. The active compounds and composi-
tions, for example, may be administered to plant parts or to 
the soil or other growth medium surrounding the roots of the 
plants or to the seed of the plant before it is sown using 
standard agricultural techniques (such as spraying). 20 effective amount of a compound of formula (I), wherein: X 
is Se; Y is C; R1 is -H, and R is substituted or unsubstituted 
aryl or substituted or unsubstituted heteroaryl; or a salt 
thereof. 
Agricultural compositions of the invention may be pre-
pared by any of the well-known techniques of agricultural 
practices, such as effective formulation and administration 
procedures. 
The dosage regimen for the compounds and/or composi- 25 
tions containing the compounds is based on a variety of 
factors, including the type of agricultural crop, the weather, 
and the season; the severity of the condition; the route of 
administration; and the activity of the particular compound 
employed. Thus the dosage regimen may vary widely. 30 
Dosage levels of the order from about 0.01 mg to about 100 
mg per kilogram of plant weight per day are useful in the 
treatment of the above-indicated conditions. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is Se; Y is C; R1 is -H, and R is substituted or unsubstituted 
aryl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is Se; Y is C; R1 is -H, and R is a substituted or unsub-Yet another aspect of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I): 
35 stituted aryl selected from the group consisting of substi-
tuted or unsubstituted phenyl, substituted or unsubstituted 
naphthalene, substituted or unsubstituted anthracene, sub-
stituted or unsubstituted phenanthrene, and substituted or 
wherein 
R,~N-R l __ J_y; 
y X 
X may be Se, S, or S=O; 
Y may be C, N, or O; 
(I) 
R may be substituted or unsubstituted aryl, substituted or 
unsubstituted heteroaryl, substituted or unsubstituted 
alkyl, substituted or unsubstituted cycloalkyl, or ORa; 
R1 may be -H, --OH, -NH2 , OR6 , CF 3 , N02 , or CN; 
Ra may be linear or branched C1 _16 alkyl groups or linear 
pegylated C4 _16 alkyl groups; and 
R6 may be linear or branched C1 _16 alkyl groups; or a salt 
thereof. 
40 
unsubstituted pyrene; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is Se; Y is C; R1 is -H, and R is substituted or unsubstituted 
45 heteroaryl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
50 is Se; Y is C; R1 is -H, and R is a substituted or unsub-
stituted heteroaryl selected from the group consisting of 
substituted or unsubstituted pyridine, substituted or unsub-
stituted quinoline, substituted or unsubstituted thiophene, 
substituted or unsubstituted pyrrole, substituted or unsub-
55 stituted furan, substituted or unsubstituted imidazole, sub-
stituted or unsubstituted oxazole, and substituted or unsub-
stituted thiazole; or a salt thereof. 
In one embodiment of the invention, subject in need of 
treatment of an infection caused by a fungal species with a 60 
therapeutically effective amount of a compound of formula 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
(I) may be an animal. Examples of animals that may be 
treated according to the invention include invertebrates and 
vertebrates. Examples of invertebrates that may be treated 
according to the invention include Apis mellifera, Droso- 65 
phila melanogaster, and Caenorhabditis elegans. Examples 
of vertebrates that may be treated according to the invention 
is Se; Y is C; R1 is -H, and R is substituted or unsubstituted 
alkyl, or substituted or unsubstituted cycloalkyl; or a salt 
thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
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effective amount of a compound of formula (I), wherein: X 
is Se; Y is C; R1 is -H, and R is substituted or unsubstituted 
alkyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is Se; Y is C; R1 is -H, and R is a C1 -C20 alkyl that is 
unsubstituted or substituted with one or more substituents 
selected from the group consisting of C1 -C6 alkyl, ---ORa, 
-SRb, -NReRd, -F, --Cl, -Br, -I, -CN, -NO2, 
phenyl, pyridyl, --CHO, -COORe, ----CO(NR~g); 
wherein each of Ra, Rb, Re, Rd, Re, Rfi and Rg are indepen-
dently selected from H or C1 -C6 alkyl; or a salt thereof. 
20 
is Se; Y is C; R1 is -H, and Risa tricyclic C3 -C20 alkyl that 
is unsubstituted or substituted with one or more substituents 
selected from the group consisting of C1 -C6 alkyl, ---ORa, 
-SRb, -NReRd, -F, --Cl, -Br, -I, -CN, -NO2, 
5 phenyl, pyridyl, -CHO, -COORe, ----CO(NR~g); 
wherein each of Ra, Rb, Re, Rd, Re, Rfi and Rg are indepen-
dently selected from H or C1 -C6 alkyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
10 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is Se; Y is C; R1 is -H, and R is adamantane; or a salt 
thereof. 
A further embodiment of the invention is anew method of 15 A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is Se; Y is C; R1 is -H, and R is selected from the group 
consisting of substituted or unsubstituted butyl, pentyl, 
hexyl, heptyl, octyl, decyl, and dodecyl; or a salt thereof. 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is S; Y is C; R1 is -H, and R is substituted or unsubstituted 
20 aryl, substituted or unsubstituted heteroaryl, substituted or 
unsubstituted alkyl, or substituted or unsubstituted 
cycloalkyl; or a salt thereof. A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 25 
is Se; Y is C; R1 is -H, and R is substituted or unsubstituted 
cycloalkyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is S; Y is C; R1 is -H, and R is substituted or unsubstituted 
aryl or substituted or unsubstituted heteroaryl; or a salt 
thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 30 
effective amount of a compound of formula (I), wherein: X 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is S; Y is C; R1 is -H, and R is substituted or unsubstituted 
is Se; Y is C; R1 is -H, and Risa monocyclic C3 -C20 alkyl 
that is unsubstituted or substituted with one or more sub-
stituents selected from the group consisting of C1 -C6 alkyl, 
-ORa, -SRb, -NReRd, -F, --Cl, -Br, -I, -CN, 
-NO2, phenyl, pyridyl, -CHO, -COORe, ----CO(NR~g); 
wherein each of Ra, Rb, Re, Rd, Re, Rfi and Rg are indepen-
dently selected from H or C1 -C6 alkyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is Se; Y is C; R1 is -H, and R is selected from the group 
consisting of substituted or unsubstituted cyclopropyl, 
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooc-
tyl, cyclodecyl, and cyclododecyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is Se; Y is C; R1 is -H, and Risa bicyclic CcC20 alkyl that 
is unsubstituted or substituted with one or more substituents 
selected from the group consisting of C1 -C6 alkyl, ---ORa, 
-SRb, -NReRd, -F, --Cl, -Br, -I, -CN, -NO2, 
phenyl, pyridyl, --CHO, -COORe, ----CO(NR~g); 
wherein each of Ra, Rb, Re, Rd, Re, Rfi and Rg are indepen-
dently selected from H or C1 -C6 alkyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is Se; Y is C; R1 is -H, and R is selected from decalin or 
norbornane; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
35 aryl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
40 is S; Y is C; R1 is -H, and Risa substituted or unsubstituted 
aryl selected from the group consisting of substituted or 
unsubstituted phenyl, substituted or unsubstituted naphtha-
lene, substituted or unsubstituted anthracene, substituted or 
unsubstituted phenanthrene, and substituted or unsubstituted 
45 pyrene; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
50 is S; Y is C; R1 is -H, and R is substituted or unsubstituted 
heteroaryl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
55 effective amount of a compound of formula (I), wherein: X 
is S; Y is C; R1 is -H, and Risa substituted or unsubstituted 
heteroaryl selected from the group consisting of substituted 
or unsubstituted pyridine, substituted or unsubstituted qui-
noline, substituted or unsubstituted thiophene, substituted or 
60 unsubstituted pyrrole, substituted or unsubstituted furan, 
substituted or unsubstituted imidazole, substituted or unsub-
stituted oxazole, and substituted or unsubstituted thiazole; or 
a salt thereof. 
A further embodiment of the invention is a new method of 
65 treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
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is S; Y is C; R1 is -H, and R is substituted or unsubstituted 
alkyl, or substituted or unsubstituted cycloalkyl; or a salt 
thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
22 
effective amount of a compound of formula (I), wherein: X 
is S; Y is C; R1 is -H, and R is selected from decalin or 
norbornane; or a salt thereof. 
A further embodiment of the invention is a new method of 
5 treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is S; Y is C; R1 is -H, and R is a tricyclic C3 -C20 alkyl that 
is unsubstituted or substituted with one or more substituents 
is S; Y is C; R1 is -H, and R is substituted or unsubstituted 
alkyl; or a salt thereof. 
A further embodiment of the invention is anew method of 10 selected from the group consisting of C1 -C6 alkyl, ---ORa, 
-SRb, -NReRd, -F, --Cl, -Br, -I, -CN, -NO2, 
phenyl, pyridyl, -CHO, -COORe, ----CO(NR_.,Rg); 
wherein each of Ra, Rb, Re, Rd, Re, Rfi and Rg are indepen-
dently selected from H or C1 -C6 alkyl; or a salt thereof. 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is S; Y is C; R1 is -H, and R is a C1 -C20 alkyl that is 15 
unsubstituted or substituted with one or more substituents 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is S; Y is C; R1 is -H, and R is adamantane; or a salt thereof. 
selected from the group consisting of C1 -C6 alkyl, ---ORa, 
-SRb, -NReRd, -F, --Cl, -Br, -I, -CN, -NO2, 
phenyl, pyridyl, --CHO, -COORe, ----CO(NR_.,Rg); 
wherein each of Ra, Rb, Re, Rd, Re, Rfi and Rg are indepen- 20 
dently selected from H or C1 -C6 alkyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is S=O; Y is C; R1 is -H, and R is substituted or 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is S; Y is C; R1 is -H, and R is selected from the group 
consisting of substituted or unsubstituted butyl, pentyl, 
hexyl, heptyl, octyl, decyl, and dodecyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is S; Y is C; R1 is -H, and R is substituted or unsubstituted 
cycloalkyl; or a salt thereof. 
25 unsubstituted alkyl, or substituted or unsubstituted 
cycloalkyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
30 effective amount of a compound of formula (I), wherein: X 
is S=O; Y is C; R1 is -H, and R is substituted or 
unsubstituted alkyl; or a salt thereof. 
A further embodiment of the invention is a new method of 35 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is S; Y is C; R1 is -H, and Risa monocyclic C3 -C20 alkyl 
that is unsubstituted or substituted with one or more sub- 40 
is S=O; Y is C; R1 is -H, and R is a C1 -C20 alkyl that is 
unsubstituted or substituted with one or more substituents 
selected from the group consisting of C1 -C6 alkyl, ---ORa, 
-SRb, -NReRd, -F, --Cl, -Br, -I, -CN, -NO2, 
phenyl, pyridyl, -CHO, -COORe, ----CO(NR_.,Rg); stituents selected from the group consisting of C1 -C6 alkyl, 
-ORa, -SRb, -NReRd, -F, --Cl, -Br, -I, -CN, 
-NO2, phenyl, pyridyl, -CHO, -COORe, ----CO(NR_.,Rg); 
wherein each of Ra, Rb, Re, Rd, Re, Rfi and Rg are indepen-
dently selected from H or C1 -C6 alkyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is S; Y is C; R1 is -H, and R is selected from the group 
consisting of substituted or unsubstituted cyclopropyl, 
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooc-
tyl, cyclodecyl, and cyclododecyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is S; Y is C; R1 is -H, and R is a bicyclic CcC20 alkyl that 
is unsubstituted or substituted with one or more substituents 
selected from the group consisting of C1 -C6 alkyl, ---ORa, 
-SRb, -NReRd, -F, --Cl, -Br, -I, -CN, -NO2, 
phenyl, pyridyl, --CHO, -COORe, ----CO(NR_.,Rg); 
wherein each of Ra, Rb, Re, Rd, Re, Rfi and Rg are indepen-
dently selected from H or C1 -C6 alkyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
wherein each of Ra, Rb, Re, Rd, Re, Rfi and Rg are indepen-
dently selected from H or C1 -C6 alkyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
45 treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is S=O; Y is C; R1 is -H, and R is selected from the group 
consisting of substituted or unsubstituted butyl, pentyl, 
50 hexyl, heptyl, octyl, decyl, and dodecyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
55 is S=O; Y is C; R1 is -H, and R is substituted or 
unsubstituted cycloalkyl; or a salt thereof. 
A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
60 effective amount of a compound of formula (I), wherein: X 
is S=O; Y is C; R1 is -H, and Risa monocyclic C3 -C20 
alkyl that is unsubstituted or substituted with one or more 
substituents selected from the group consisting of C1 -C6 
alkyl, -ORa, -SRb, -F, -Cl, -Br, -I, ----CN, -NO2, 
65 phenyl, pyridyl, -CHO, -COORe, ----CO(NR_.,Rg); 
wherein each of Ra, Rb, Re, Rd, Re, Rfi and Rg are indepen-
dently selected from H or C1 -C6 alkyl; or a salt thereof. 
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A further embodiment of the invention is a new method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: X 
is S=O; Y is C; R1 is -H, and R is selected from the group 5 
consisting of substituted or unsubstituted cyclopropyl, 
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooc-
tyl, cyclodecyl, and cyclododecyl; or a salt thereof. 
24 
X=S; Y=C; R1~H, and 
Afurtherembodimentoftheinventionisanewmethodof 10 X=S; Y=C; R1~H, and 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I), wherein: 
X=Se; Y=C; R1~H, and 
X=S; Y=C; R1~H, and 
X=S; Y=C; R1~H, and 
X=S; Y=C; R1~H, and 
X=S; Y=C; R1~H, and 
X=S; Y=C; R1~H, and 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
~ 
Br; 
X=S; Y=C; R1~H, and 
X=S; Y=C; R1~H, and 
Br 
R-~ 
Br; 
X=S; Y=C; R1~H, and 
X=S; Y=C; R1~H, and 
OMe 
R-~ 
OMe; 
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X=S; Y=C- _ 25 
'R1 H, and X=S; Y=C- _ 26 'R1 -H, and 
R-u -r)11; 
X=S; Y=C- R -
' 1 -H, and 
10 
X=S; Y=C- R -
' i H, and 
15 
X=S; Y=C- R -
' i H, and 
20 
X=S; Y=C- R -
' i H, and 
25 
X=S; Y=C- R -
' i H, and 
X=S; Y=C- R -
' i -H, and 30 
35 X=S; Y=C- R -' 1 H, and 
X=S; Y=C- R -
' 1 -H, and 
40 
45 X=S; Y=C- R -
' i -H, and 
X=S; Y=C- R -
' 1 H, and 50 
55 
X=S; Y=C- R -
' i -H, anc 
X=S; Y=C- R -
' 1 H, and 60 
65 
27 
X=S; Y=C; R1~H, and 
X=S; Y=C; R1~H, and 
X=S; Y=C; R1~H, and 
X=S; Y=C; R1~H, and 
X=S; Y=C; R1~H, and 
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X=S=O; Y=C; R1~H, and 
A further embodiment of the invention is a method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I) or a salt 
thereof, wherein the fungal species is a Candida, Aspergil-
15 lus, Trichophyton, Fusarium, Microsporum, Blumeria, 
Podosphaera, Sphaerotheca, Phakopsora, Puccinia, Uro-
myces, Peronospora, Phytophthora, Plasmopara, Pythium, 
Alternaria, Cercospora, Cladiosporium, Colletotrichum, 
Cycloconium, Cochliobolus, Gloeosporium, Glomerella, 
Guignardia, Leptosphaeria, Magnaporthe, Botrytis, Peni-
20 cillium, Sclerotinia, Verticillium, Rhizoctonia, Sclerotium, 
Nectria, Monilinia, and Helminthosporium species. 
A further embodiment of the invention is a method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
25 effective amount of a compound of formula (I) or a salt 
thereof, wherein the fungal species is selected from the 
group consisting of Candida albicans, Candida glabrata, 
Candida krusei, or Candida parapsilosis. 
A further embodiment of the invention is a method of 
30 treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I) or a salt 
thereof, wherein the fungal species is selected from the 
group consisting of Aspergillus flavus, Aspergillus nidulans, 
35 and Aspergillus terreus. A further embodiment of the invention is a method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I) or a salt 
thereof, wherein the fungal species is selected from the 
40 group consisting of Trichophyton rubrum, Trichophyton 
tonsurans, and Trichophyton interdigitale. 
A further embodiment of the invention is a method of 
treating an infection caused by a fungal species, comprising 
administering to a subject in need thereof a therapeutically 
45 effective amount of a compound of formula (I) or a salt 
thereof, wherein the fungal species is selected from the 
group consisting of Microsporum canis and Microsporum 
gypseum. 
In one embodiment of the invention, the subject in need 
50 of treatment of an infection caused by a fungal species with 
a therapeutically effective amount of a compound of formula 
(I) may be a mammal. Examples of mammals that may be 
treated according to the invention include humans, primates, 
horses, sheep, pigs, cows, mice, rats, rabbits, dogs, and cats. 
55 In another embodiment of the invention, the subject in 
need of treatment of an infection caused by a fungal species 
with a therapeutically effective amount of a compound of 
formula (I) may be an agricultural crop. Examples of agri-
cultural crops that may be treated according to the invention 
60 include grains, vegetables, and fruit. 
A further embodiment of the invention is a method of 
treating powdery mildew diseases comprising administering 
to a subject in need thereof a therapeutically effective 
amount of a compound of formula (I) or a salt thereof, 
65 wherein the powdery mildew diseases include (1) Blumeria 
diseases caused, for example, by Blumeria graminis; (2) 
Podosphaera diseases caused, for example, by Podosphaera 
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leucotricha; and (3) Sphaerotheca diseases caused, for 
example, by Sphaerotheca fuliginea. 
A further embodiment of the invention is a method of 
treating rust diseases comprising administering to a subject 
30 
A further embodiment of the invention is a method of 
treating canker, broom and dieback diseases comprising 
administering to a subject in need thereof a therapeutically 
effective amount of a compound of formula (I) or a salt 
5 thereof, wherein the canker, broom and dieback diseases 
include Nectria diseases caused, for example, by Nectria 
galligena. 
in need thereof a therapeutically effective amount of a 
compound of formula (I) or a salt thereof, wherein the rust 
diseases include (1) Phakopsora diseases caused, for 
example, by Phakopsora pachyrhizi and Phakopsora mei-
bomiae; (2) Puccinia diseases caused, for example, by 
Puccinia recondite, and Puccinia triticina; and (3) Uromy- 10 
ces diseases caused, for example, by Uromyces appendicu-
latus. 
A further embodiment of the invention is a method of 
treating oomycete diseases comprising administering to a 15 
subject in need thereof a therapeutically effective amount of 
a compound of formula (I) or a salt thereof, wherein the 
oomycete diseases include (1) Peronospora diseases caused, 
for example, by Peronospora pisi and Peronospora brassi-
cae; (2) Phytophthora diseases caused, for example, by 20 
Phytophthora infestans; (3) Plasmopara diseases caused, 
for example, by Plasmopara viticola; and (4) Pythium 
diseases caused, for example, by Pythium ultimum. 
A further embodiment of the invention is a method of 
treating leafspot, leaf blotch and leaf blight diseases com- 25 
prising administering to a subject in need thereof a thera-
peutically effective amount of a compound of formula (I) or 
a salt thereof, wherein the leafspot, leaf blotch, and leaf 
blight diseases include (1) Alternaria diseases caused, for 
example, by Alternaria solani; (2) Cercospora diseases 30 
caused, for example, by Cercospora beticola; (3) Cladio-
sporium diseases caused, for example, by Cladiosporium 
cucumerinum; ( 4) Colletotrichum diseases caused, for 
example, by Colletotrichum lindemuthianum; (5) Cycloco-
nium diseases caused, for example, by Cycloconium oleagi- 35 
num; (6) Cochliobolus diseases caused, for example, by 
Cochliobolus sativus; (7) Gloeosporium diseases caused, for 
example, by Gloeosporium laeticolor; (8) Glomerella dis-
eases caused, for example, by Glomerella cingulata; (9) 
Guignardia diseases caused, for example, by Guignardia 40 
bidwellii; (10) Leptosphaeria diseases caused, for example, 
by Leptosphaeria maculans; and (11) Magnaporthe diseases 
caused, for example, by Magnaporthe grisea. 
A further embodiment of the invention is a method of 
treating Blight Diseases comprising administering to a sub-
ject in need thereof a therapeutically effective amount of a 
compound of formula (I) or a salt thereof, wherein the blight 
diseases include Monilinia diseases caused, for example, by 
Monilinia laxa. 
A further embodiment of the invention is a method of 
treating diseases of flowers and seeds comprising adminis-
tering to a subject in need thereof a therapeutically effective 
amount of a compound of formula (I) or a salt thereof, 
wherein the diseases of flowers and seeds include (1) 
Botrytis diseases caused, for example, by Botrytis cinerea; 
and (2) Helminthosporium diseases caused, for example, by 
Helminthosporium solani. 
The compounds of the invention can be used, alone or in 
combination with other therapeutic agents, in the treatment 
of various conditions or disease states. The compound(s) of 
the invention and other therapeutic agent(s) may be may be 
administered simultaneously ( either in the same dosage form 
or in separate dosage forms) or sequentially. 
Two or more compounds may be administered simulta-
neously, concurrently or sequentially. Additionally, simulta-
neous administration may be carried out by mixing the 
compounds prior to administration or by administering the 
compounds at the same point in time but at different ana-
tomic sites or using different routes of administration. 
The phrases "concurrent administration," "co-administra-
tion," "simultaneous administration," and "administered 
simultaneously" mean that the compounds are administered 
in combination. 
The invention includes the use of a combination of a 
compound of Formula (I) and one or more additional 
pharmaceutically active agent(s ). If a combination of active 
agents is administered, then they may be administered 
sequentially or simultaneously, in separate dosage forms or 
combined in a single dosage form. Accordingly, the inven-
tion also includes pharmaceutical compositions comprising A further embodiment of the invention is a method of 
treating fruit rot and mold diseases comprising administer-
ing to a subject in need thereof a therapeutically effective 
amount of a compound of formula (I) or a salt thereof, 
wherein the fruit rot and mold diseases include (1) Asper-
gillus diseases caused, for example, by Aspergillus flavus; 
(2) Botrytis diseases caused, for example, by Botrytis 
cinerea; (3) Penicillium diseases caused, for example, by 
Penicillium expansum and Penicillium purpurogenum; (4) 
Sclerotinia diseases caused, for example, by Sclerotinia 
sclerotiorum; and (5) Verticillium diseases caused, for 
example, by Verticillium alboatrum. 
45 an amount of: (a) a first agent comprising a compound of 
Formula I or a pharmaceutically acceptable salt of the 
compound; (b) a second pharmaceutically active agent; and 
( c) a pharmaceutically acceptable carrier, vehicle or diluent. 
A further embodiment of the invention is a method of 
treating seed- and soil-borne decay, mold, wilt, rot, and 
damping-off diseases comprising administering to a subject 
in need thereof a therapeutically effective amount of a 
compound of formula (I) or a salt thereof, wherein the seed-
and soil-borne decay, mold, wilt, rot, and damping-off 
diseases include (1) Fusarium diseases caused, for example, 
by Fusarium culmorum; (2) Phytophthora diseases caused, 
for example, by Phytophthora cactorum; (3) Rhizoctonia 
diseases caused, for example, by Rhizoctonia solani; and ( 4) 
Sclerotium diseases caused, for example, by Sclerotium 
rolfsii; 
The compounds of this invention may also be used in 
50 conjunction with other pharmaceutical agents for the treat-
ment of the diseases, conditions and/or disorders described 
herein. Therefore, methods of treatment that include admin-
istering compounds of the invention in combination with 
other pharmaceutical agents are also provided. Suitable 
55 pharmaceutical agents that may be used in combination with 
the compounds of the invention include, without limitation: 
include azoles ( e.g., fluconazole (FLC), itraconazole (ITC), 
posaconazole (POS), and voriconazole (VOR)), polyenes 
(e.g., amphotericin B (AmB), nystatin (NYS), and candici-
60 din (CAN)), allylamines ( e.g., butenafine, naftifine, and 
terbinafine ), and echinocandins ( e.g., micafungin, caspo-
fungin, and anidulafungin). 
Pharmaceutical compositions of the invention may con-
tain pharmaceutical excipients including antiadherents, 
65 binders, disintegrants, fillers, diluents, glidants, lubricants, 
preservatives, and the like, which are known to a person 
skilled in the art. 
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Suitable pharmaceutically acceptable excipients include, 
but are not limited to, antioxidants, preservatives, coloring, 
flavoring and diluting agents, emulsifying agents, suspend-
ing agents, solvents, fillers, bulking agents, buffers, delivery 
vehicles, diluents, and/or pharmaceutical adjuvants. 
EXAMPLES 
Ebsulfur and its analogues were prepared according to the 
procedures disclosed in Ngo, H. X. et al. (2016) Develop-
ment of ebsulfur analogues as potent antibacterials against 
methicillin-resistant Staphylococcus aureus. Bioorg. Med. 
Chem. doi: 10.1016/j.bmc.2016.03.060, which is incorpo-
rated herein by reference in its entirety. 
The antifungal agents amphotericin B (AmB), fluconazole 
(FLC), itraconazole (ITC), posaconazole (POS), and vori-
conazole (VOR) were obtained from AK Scientific (Union 
City, Calif., USA) and used without further purification. 
AmB, FLC, ITC, POS, and VOR were dissolved in DMSO 
at a final concentration of 5 mg/mL. All these antifungal 
agent stocks were stored at -20° C. 
Compounds l-4n, which feature ebselen (1) and ebsulfur 
(2a) as the main scaffolds, were evaluated. From the ebsulfur 
scaffold, the library was further organized into three sub-
series: analogues with aromatic substituents (2 series, 2a-o ), 
analogues with aliphatic substituents (3 series, 3a-o ), and 
oxidized sulfoxide analogues ( 4 series, 4e, 4f, and 4n): 
32 
USA). Spectrophotometric and colorimetric measurements 
in 96-well plates were performed using a SpectraMax MS 
spectrometer (Molecular Devices, Sunnyvale, Calif., USA). 
Yeast strains Candida albicans ATCC 10231 (strainA), C. 
5 albicans ATCC 64124 (strain B), and C. albicans ATCC 
MYA-2876(S) (strain C) were kindly provided by Dr. Jon Y. 
Takemoto (Utah State University, Logan, UT, USA). C. 
albicans ATCC MYA-90819(R) (strain D), C. albicans 
ATCC MYA-2310(S) (strain E), C. albicans ATCC 1237(R) 
10 (strain F), C. albicans ATCC MYA-1003(R) (strain G), 
Candida glabrata ATCC 2001 (strain H), Candida krusei 
ATCC 6258 (strain I), and Candida parapsilosis ATCC 
22019 (strain J) were obtained from the American Type 
Culture Collection (ATCC, Manassas, Va., USA). The (S) 
15 and (R) indicate that ATCC reports these strains to be 
susceptible (S) and resistant (R) to ITC and FLC. The 
filamentous fungal strains Aspergillus flavus ATCC MYA-
3631 (strain K), and Aspergillus terreus ATCC MYA-3633 
(strain M) were also obtained from the American Type 
20 Culture Collection (ATCC, Manassas, Va., USA). Aspergil-
lus nidulans ATCC 38163 (strain L) was kindly provided by 
Dr. Jon S. Thorson (University of Kentucky, Lexington, Ky., 
USA), respectively. Yeast strains were cultured at 35° C. 
Filamentous fungal strains were cultured at 25° C. and the 
25 spores were harvested. All fungal strains were cultured in 
RPMI 1640 medium (catalog # R6504, Sigma-Aldrich 
Chemical Co., St. Louis, Mo.) buffered to pH 7.0 with 0.165 
M morpholinepropanesulfonic acid (MOPS) buffer (Sigma-
Aldrich Chemical Co.). 
(Series 1) 30 The human embryonic kidney cell line HEK-293 (ATCC 
Ebselen 
(Series 2) 
Ebsulfur 
CRL-1573) and the murine macrophage cell line J774A.1 
(ATCC TIB-67) were kindly provided by Dr. Matthew S. 
Gentry and Dr. David J. Feola (University of Kentucky, 
Lexington, Ky., USA), respectively. The HEK-293 cell line 
35 was grown in Dulbecco's Modified Eagle's Medium 
(DMEM) (ATCC, Manassas, Va., USA) with 10% fetal 
bovine serum (FBS) (ATCC, Manassas, Va., USA) and 1 % 
Pen/Strep (ATCC, Manassas, Va., USA). The J774A.1 cell 
line was grown under the same conditions, except that the 
40 medium used was a different type of DMEM (catalog 
#30-2002, ATCC, Manassas, Va., USA). The HEK-293 cell 
line was passaged by trypsinization with 0.05%-trypsin-0.53 
mM EDTA (ATCC, Manassas, Va., USA). The J774A.1 cell 
line was passaged mechanically by cell scrapers (ATCC, 
(Series 3) 45 Manassas, Va., USA). Cell confluency was observed by 
Ebsulfur 
~N-R U--s; 
\\ 
0 
Ebsulfur 
(Series 4) 
Fungal MIC determination experiments were performed 
using untreated 96-well plates (Corning). Cells were 
counted either by using a hemocytometer (Hausser Scien-
tific, Horsham, Pa., USA) or by measuring optical density at 
attenuance of 600 nm (OD600) by using a Genesys 20 
spectrophotometer (Thermo Scientific, Waltham, Mass., 
50 
using a Nikon Eclipse TSl00 microscope (Minato, Tokyo, 
Japan). 
Example 1 
Antifungal Activity 
The MIC values against fungal strains were determined 
based on a previously published protocol. MIC values for 
55 ebsulfur (2a) analogues against fungal cells were evaluated 
in 96-well plates as described in the CLSI document M27-
A3 with minor modifications. Some of the fungal strains, 
such as C. albicans ATCC 64124 (strain B) tend to produce 
pseudohyphae (filaments) in RPMI 1640 medium, which 
60 was found to hinder cell counting when using a hemocy-
tometer. Therefore, potato dextrose broth (PDB) was used to 
grow the yeast inocula of all strains tested, which were later 
diluted in RPMI 1640 medium to perform determination of 
MIC values. Minor modifications included growing yeast 
65 cells in PDB for 24-48 h at 35° C. at 200 rpm, diluting in 
RPMI 1640 medium to a concentration of lxl06 cells/mL 
(as determined by using a hemocytometer or an OD600 of 
US 10,544,112 B2 
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0.12) and using a final inoculum size of 5xl03 CFU/mL for 
all the assays. The tested compounds (10 mg/mL) were 
diluted to the working stocks (500 µg/mL) by addition of 
DMSO. Two-fold serial dilution of the working stocks was 
prepared by addition ofRPMI 1640 medium (100 µL) and 5 
cell suspension (100 µL) to 96-well microtiter plate to 
achieve final drug and inoculum concentrations ranging 
from 12.5-0.02 µg/mL and 5xl03 CFU/mL, respectively. 
Plates were incubated for 48 h at 35° C. 
The MIC values for all tested compounds studied were 10 
defined as the lowest drug concentration that inhibits the 
visible growth of fungal strains after a 48-h incubation 
period. MIC assays for the spore-forming filamentous fungi, 
such as strain A. flavus ATCC MYA-3631 (strain K), were 
performed in a similar fashion. The filamentous fungal 15 
strains were first cultured at 25° C. on potato dextrose agar 
(PDA) plates for 3-5 days or until confluent. Spores were 
collected by washing the surface of the agar plates with dd 
H20 (5 mL) and then isolated the spores by gravity filtration 
(the spores are H20 soluble). The spores were then counted 20 
by using a hemocytometer and added to the MIC assays to 
achieve a final concentration of 5x 103 cells/mL. Researchers 
working with spores should wear a facemask to prevent 
spore inhalation. These MIC data are presented in Tables 1. 
Compounds of formula (I) were evaluated for whole-cell 25 
activity against a panel of clinically relevant fungal strains 
(Table 1). The ebsulfur scaffold was further organized into 
three sub-series: (1) analogues with aromatic substituents (2 
series, 2a-o ), including mono- and disubstituted phenyl rings 
(2a-k), naphthyl (21), and nitrogen-containing aromatic het- 30 
erocycles (2m-o ); (2) analogues with aliphatic substituents 
(3 series, 3a-o ), including linear alkyl chains (3a-d), 
branched alkyl chains (3e-g), alkyl with terminal phenyl ring 
(3h-j), aliphatic rings (3k-n), and adamantyl (3o ); and (3) 
oxidized sulfoxide analogues ( 4 series, 4e, 4f, and 4n). 35 
Commercially available AmB, FLC, ITC, POS, and VOR 
were used as positive controls. 
TABLE 1 
Cpd 
# R A B C 
Yeast Strains 
D E F G H 
t-0 
t-0 
t-0--, 
12.5 12.5 12.5 1.56 3.13 >12.5 12.5 1.56 1.56 
2a 12.5 >12.5 12.5 3.13 6.25 >12.5 >12.5 6.25 3.13 
2b 3.13 6.25 3.13 3.13 3.13 6.25 1.56 6.25 3.13 
2c t-0--c, 3.13 >12.5 12.5 6.25 6.25 6.25 12.5 6.25 3.13 
2d 3.13 3.13 1.56 3.13 0.78 1.56 3.13 6.25 3.13 
34 
(Series 1) 
Ebselen 
(Series 2) 
Ebsulfur 
(Series 3) 
Ebsulfur 
(Series 4) 
Ebsulfur 
F ilarnentous Fungi 
K L M 
6.25 6.25 1.56 1.56 
12.5 6.25 6.25 6.25 
12.5 6.25 12.5 12.5 
12.5 6.25 6.25 6.25 
6.25 12.5 12.5 12.5 
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TABLE I-continued 
Cpd Yeast Strains Filamentous Fungi 
# R A B C D E F G H K L M 
2e t-0---< 3.13 3.13 3.13 3.13 3.13 6.25 3.13 3.13 3.13 3.13 6.25 6.25 6.25 
2f ! ( ) 12.5 12.5 >12.5 12.5 >12.5 12.5 12.5 6.25 6.25 12.5 12.5 12.5 12.5 
2g ~ >12.5 12.5 12.5 12.5 >12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 
Br 
2h 3.13 3.13 3.13 3.13 3.13 3.13 3.13 3.13 3.13 3.13 6.25 12.5 12.5 
2i Br 3.13 6.25 6.25 6.25 6.25 3.13 6.25 6.25 6.25 6.25 12.5 3.13 12.5 
~ 
Br 
2j ~ 3.13 6.25 1.56 12.5 0.78 3.13 3.13 12.5 12.5 12.5 12.5 12.5 12.5 
2k OMe 12.5 12.5 3.13 3.13 1.56 12.5 12.5 6.25 6.25 6.25 6.25 6.25 6.25 
~ 
OMe 
21 
13 
6.25 12.5 >12.5 3.13 >12.5 >12.5 6.25 12.5 6.25 12.5 12.5 12.5 12.5 
j 
2m t-0 6.25 6.25 12.5 6.25 6.25 6.25 6.25 12.5 6.25 12.5 12.5 12.5 12.5 
2n t-0-c, 12.5 12.5 12.5 >12.5 12.5 12.5 12.5 >12.5 >12.5 >12.5 >12.5 >12.5 >12.5 
Cpd 
# 
2o 
3a 
3b 
3c 
3d 
3e 
3f 
3g 
3h 
3i 
3j 
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TABLE I-continued 
Yeast Strains 
A B C D E F G H 
ND ND ND ND ND ND ND ND ND 
1.56 0.39 0.78 1.56 0.39 0.78 0.78 1.56 0.78 
1.56 1.56 0.78 1.56 0.78 1.56 0.78 1.56 0.78 
6.25 1.56 6.25 3.13 1.56 1.56 1.56 1.56 1.56 
>12.5 >12.5 >12.5 >12.5 >12.5 >12.5 >12.5 12.5 >12.5 
0.78 1.56 0.78 0.78 0.78 0.78 1.56 1.56 0.39 
1.56 0.78 1.56 0.78 0.78 0.78 1.56 1.56 0.39 
0.78 1.56 3.13 1.56 1.56 1.56 1.56 1.56 0.78 
0.39 1.56 1.56 1.56 1.56 1.56 0.78 1.56 0.39 
1.56 1.56 1.56 1.56 1.56 1.56 1.56 1.56 1.56 
6.25 3.13 6.25 3.13 6.25 6.25 6.25 1.56 1.56 
38 
Filamentous Fungi 
K L M 
ND ND ND ND 
0.78 ,;0.02 ,;0.02 ,;0.02 
0.78 ,;0.02 ,;,;0.02 ,;0.02 
0.78 ,;0.02 ,;0.02 ,;0.02 
>12.5 >12.5 >12.5 >12.5 
0.78 0.20 0.02 0.10 
1.56 0.20 0.02 0.10 
1.56 0.10 0.10 0.10 
0.78 0.78 0.39 0.39 
1.56 0.78 0.20 0.20 
6.25 0.78 0.20 0.20 
Cpd 
# 
3k 
31 
3m 
3n 
3o 
4e 
4f 
4n 
AmB 
FLC 
ITC 
POS 
VOR 
R 
kJ 
K) 
t-0 
t--Q 
b© 
~ 
~ 
t-0 
39 
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TABLE I-continued 
Yeast Strains 
A B C D E F G H 
0.39 1.56 0.78 0.39 0.39 0.39 0.78 0.78 0.39 
0.78 1.56 3.13 0.78 1.56 0.78 1.56 1.56 0.78 
1.56 1.56 3.13 1.56 3.13 1.56 3.13 3.13 0.39 
3.13 3.13 6.25 6.25 6.25 6.25 6.25 3.13 0.39 
ND ND ND ND ND ND ND ND ND 
>12.5 >12.5 >12.5 >12.5 >12.5 >12.5 >12.5 >12.5 >12.5 
>12.5 >12.5 >12.5 >12.5 >12.5 >12.5 >12.5 >12.5 >12.5 
>12.5 >12.5 >12.5 >12.5 >12.5 >12.5 >12.5 >12.5 >12.5 
3.9 3.9 1.95 0.98 1.95 3.9 3.9 1.95 
62.5a >125a 15.6a >125a >125a 62.5a 62.5a >31.2 
0.5a >62.5a 7.8a 31.2a 31.2a 31.2a 31.2a 7.8 
0.5a >62.5a 7.8a 31.2a 31.2a 15.6a 15.6a 0.12 
7.8 >31.2 0.975 1.95 1.95 0.975 7.8 0.06 
3.9 
>31.2 
0.48 
0.06 
0.12 
40 
1.56 
1.56 
3.13 
3.13 
ND 
>12.5 
>12.5 
>12.5 
1.95 
1.95 
0.12 
<0.03 
<0.03 
Filamentous Fungi 
K 
0.20 
0.20 
0.10 
,;0.02 
ND 
>12.5 
>12.5 
>12.5 
15.6 
6.25 
0.48 
0.24 
0.24 
L 
0.10 
0.20 
0.20 
0.05 
ND 
>12.5 
>12.5 
>12.5 
15.6 
6.25a 
0.195a 
0.195a 
0.03 
M 
0.10 
0.20 
0.20 
,;0.02 
ND 
>12.5 
>12.5 
>12.5 
3.9 
62.5 
0.975 
0.48 
0.12 
Yeast strains: A= Candida albicans ATCC 10231, B = C. albicans ATCC 64124, C = C. albicans ATCC :rvrYA-2876 S), D = C. albicans ATCC 90819(R), E = C. albicans ATCC 
MYA-2310(S), F = C albicans ATCC MYA-1237(R), G = C albicans ATCC MYA-1003(R), H = Candida glabrata ATCC 2001, I= Candida krusei ATCC 6258, J = Candida 
parapsilosis ATCC 22019. NOTE: Here, the (S) and (R) indicate that ATCC reports these strains to be susceptible (S) and resistant (R) to ITC and FLC. 
Filamentous fungi: K = Aspergillusflavus ATCC :rvrYA-3631, L = Aspergillus nidulans ATCC 38163, M = Aspergi.llus terreus ATCC :rvrYA-3633. 
Known antifungal agents: ArnB = amphotericin B, FLC = fluconazole, ITC = itraconazole, POS = posaconazole, and VOR = voriconazole. 
aThese values were previously reported in Shrestha, S. K. et al. (2015) Arnphiphilic tobramycin analogues as antibacteral and antifungal agents. Antimicrob. Agents Chemother. 59, 
4861-4869. 
hpor yeast strains: MIC-0 values are reported for compounds 1-4n and AmB, whereas MIC-2 values are reported for azoles. For filamentous fungi, MIC-0 values are reported for all 
copmounds. 
ND indicates that MIC values were not determined due to solubility issues with the compound. 
The MIC values listed for the controls were either tested 
herein or acquired from previously published manuscripts 
on unrelated antifungal agents, which are hereby incorpo-
rated by reference in their entirety. Shrestha, S. K. et al. 
(2015) Amphiphilic tobramycin analogues as antibacterial 
and antifungal agents. Antimicrob. Agents Chemother. 
59,4861-4869. For the controls, AmB, as expected, was the 
60 
most active against both Candida and Aspergillus strains 
with MIC values ranging from 0.98-15.6 µg/mL. Despite its 
potent antifungal activity, it should be noted that AmB, even 
with the liposomal formulations, has been well known for its 
65 severe and potentially lethal side effects such as nephrotox-
icity and hypokalemia. Deray, G. (2002) Amphotericin B 
nephrotoxicity. J. Antimicrob. Chemother. 49 Suppl 1, 
US 10,544,112 B2 
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37-41; Moen, M. D. et al. (2009) Liposomal amphotericinB: 
a review of its use as empirical therapy in febrile neutropenia 
and in the treatment of invasive fungal infections. Drugs 69, 
361-392. FLC, the most popular and well-tolerated FDA 
approved antifungal agent, was fairly inactive against the 5 
panel of fungal strains presented here, with MIC values 
mostly from >31.2->125 µg/mL (except against C. parap-
silosis (strain J), MIC=l.95 µg/mL). ITC, POS, and VOR 
displayed similar activity against the strains presented here, 
with MIC values mostly ranging from <0.03-31.2 µg/mL. 10 
The azole compounds, however, are potent inhibitors of 
human cytochrome P450 enzymes, which somewhat limit 
their applications due to drug-drug interactions with co-
administered drugs. Dvorak, Z. (2011) Drug-drug interac- 15 
tions by azole antifungals: Beyond a dogma of CYP3A4 
enzyme activity inhibition. Toxicol. Lett. 202, 129-132. ITC 
and VOR are also generally not as well tolerated as FLC. 
Wang, J. L. et al. (2010) Systematic review and meta-
analysis of the tolerability and hepatotoxicity of antifungals 20 
in empirical and definitive therapy for invasive fungal 
infection. Antimicrob. Agents Chemother. 54, 2409-2419. To 
effectively evaluate the activities of the compounds of the 
invention, poor, good, very good, and excellent activity are 
respectively defined as ;;,;12.5 µg/mL, 1.56-6.25 µg/mL, 25 
0.39-0.78 µg/mL, and s0.10 µg/mL, respectively. 
Ebselen 
42 
with F<Cl<Br. The SAR comparison for these compounds 
was found to be flat, with all three compounds generally 
displaying MIC values from 1.56-6.25 µg/mL. Compound 
2e displayed good MIC values (3.13-6.25 µg/mL) similar to 
those of 2b-d. Lastly, p-ethinyl analogue (2f) was found to 
display mostly poor activity against Candida strains (> 12.5 
µg/mL). 
The m-monosubstituted analogues (2g,h) and the 3,5-
disubstituted analogues (2i-k) were examined next. While 
them-Br substitution of 2g was not beneficial at all (> 12.5 
µg/mL) against Candida strains, the m-iPr (2h), m,m-di-Br 
(2i), m,m-di-Me (2j), and m,m-di-OMe (2k) analogues were 
overall better tolerated with good to moderate MIC values 
(3.13-> 12.5 µg/mL). By comparing the p-substituted ana-
logues 2d,e and their m-substituted counterparts 2g,h, it was 
discovered that switching from p-Br (2d) tom-Br (2g) led to 
loss of activity, whereas switching from p-iPr (2e) and m-iPr 
(2h) led to compounds which displayed very similar MIC 
values. Overall, the activity of these compounds appeared to 
weakly correlate with the number or the positions of the 
substituents on the phenyl ring. 
Analogues with complex aromatic rings, such as the 
naphthyl (21), pyridyl (2m,n), and quinolinyl (2o), were 
examined next. Compounds 21,m displayed good to poor 
activity (6.25-> 12.5 µg/mL), while compound 2n was poorly 
active (>12.5 µg/mL) and 2o could not be evaluated due to 
solubility issues in the RPMI 1640 medium. 
Thus, the ebselen 2 series resulted in analogues with 
30 
mostly good MIC values that are comparable to the parent 
ebsulfur (2a). In particular, compounds 2d, 2e, 2h, and 2i 
displayed incrementally improved MIC values when com-
pared to those of ebsulfur (2a). 
Ebselen 35 
Ebselen (1) was tested first against the panel of Candida 
strains (A-J). Ebselen (1) displayed good activity against 
strains D, E, H, I, and J (1.56-6.25 µg/mL) and poor activity 40 
against strains A, B, C, F, and G (;;,;12.5 µg/mL). When 
compared to the controls, these MIC values were generally 
better than the MIC values of the azoles ( except against 
strains A and H-J), but were worse than those of AmB. Next, 
ebsulfur (2a) was evaluated. Ebsulfur (2a) displayed a very 45 
similar anti-Candida profile to that of ebselen (1). In par-
ticular, ebsulfur (2a) and ebselen (1) displayed good and 
poor activity against the same Candida strains. With the 
exception of strain J, 2a was active against strains D, E, H, 
and I (1.56-6.25 µg/mL) and poorly active against strains A, 50 
B, C, F, G, and J (;;,;12.5 µg/mL). This finding demonstrates 
that replacing the Se atom with the S atom does not 
compromise antifungal activity. 
Ebsulfur and Ebsulfur 2 Series 
Ebsulfur 3 Series 
Ebsulfur Series 3 
R ~ substituted or unsubstituted alkyl or cycloalkyl 
Inspired by the observation that coupling linear alkyl 
chains to aminoglycoside antibiotics resulted in a significant 
improvement of their antifungal activity, ebsulfur analogues 
with linear alkyl chains of5-12 carbons (C5 , C6 , C8 , and Cw 
3a-d) were generated and their antifungal activities were 
examined. Fosso, M. Y. et al. (2015) Synthesis and bioac-
tivities of kanamycin B-derived cationic amphiphiles. J. 
Med. Chem. 58, 9124-9132; Shrestha, S. K. et al. (2015) 
Amphiphilic tobramycin analogues as antibacterial and anti-
Ebsulfur Series 2 
55 fungal agents. Antimicrob. Agents Chemother. 59,4861-
4869; Chang, C. W. and Takemoto, J. Y. (2014) Antifungal 
amphiphilic aminoglycosides. Med Chem Comm 5, 1048-
1057; Fosso, M. et al. (2015) Structure-activity relationships 
for antibacterial to antifungal conversion of kanamycin to 
R ~ substituted or unsubstituted myl or heteromyl 
Compounds 2b-d were systematically prepared to con-
tainp-substituted halogen atoms that increased in bulkiness 
60 amphiphilic analogues. J. Org. Chem. 80, 4398-4411; Fosso, 
M. Y. et al. (2014) New trends in aminoglycosides use. Med 
Chem Comm 5,1075-1091. Because previous work with 
aminoglycosides where tobramycin and kanamycin ana-
logues with C12 and C14 alkyl chains displayed the best 
65 antifungal activity, it was hypothesized that the ebsulfur 
analogue with the longest alkyl chain (3d) would be the most 
active. However, it was surprisingly discovered that ebsulfur 
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analogues with shorter alkyl chains, such as C5 (3a) and C6 
(3b ), were remarkably effective with very good to good MIC 
values against all Candida strains (0.39-1.56 µg/mL). The 
Cg analogue (3c) was slightly worse when compared to the 
C5 (3a) and C6 (3b) analogues (specifically against strains A 5 
and C), and the C12 analogue (3d) displayed poor MIC 
values (> 12.5 µg/mL). 
With respect to anti-Candida, ebsulfur analogue 3a was 
20- to 320-fold more potent in MIC values (except against 
strain J) than FLC. When compared to AmB, ebsulfur 10 
analogue 3a was 1.25- to 10-fold more active. 
Branched alkyl ebsulfur analogues, such as iso-butyl (3e) 
and iso-amyl (3f) analogues, were also evaluated. Both 3e 
and 3f were equally as effective as 3a and 3b (0.39-1.56 15 
µg/mL). In addition, the tent-butyl ebsulfur analogue 3g was 
also as effective as 3a-f (within 2-fold dilution, 0.78-3.13 
µg/mL). Thus, against Candida strains, analogues with ali-
phatic alkyl chains (linear or branched) were found to be 
very beneficial, which could possibly be attributed to the 20 
added rotational flexibility. 
In addition, ebsulfur analogues with a phenyl ring con-
nected to the main ebsulfur scaffold via methylene linkers 
(Ci, (3h), C2 (31), and C3 (3j)) were evaluated. It was found 
that the C1 and C2 -linker analogues (3h,i) had better MIC 25 
values compared to 2a (0.39-1.56 µg/mL). However, the 
C3 -linker analogue (3j) was not as potent (1.56-62.5 µg/mL). 
Thus, it was observed that addition of flexible methylene 
linkers were well tolerated up to two carbons. 
44 
the electrophilic Se-N bond to covalently bind to cysteine 
residues of multiple enzyme targets. 
Invasive aspergillosis is highly correlated with fulminant 
development and poor prognosis. Compounds with potent 
anti-Aspergillus activity are considered to be of great valu-
able. Thus, the compounds of the invention were tested 
against freshly harvested spores of three Aspergillus strains: 
A. flavus (strain K), A. nidulans (strain L), and A. terreus 
(strain M). Overall, the compounds of the invention were 
mostly active against Aspergillus strains and the SAR trends 
observed from the study with Candida strains were trans-
latable to Aspergillus strains. Aromatic analogues (2a-o) 
exhibited good to poor activity against strains K-M (1.56-
12.5 µg/mL). Linear-chain C5 , C6 , and Cg analogues (3a-c) 
displayed excellent activity at ng/mL concentrations (s0.02-
0.20 µg/mL). These results were equivalent or slightly better 
when comparing them to VOR (0.03-0.24 µg/mL), the gold 
standard for the treatment of invasive aspergillosis. Other 
analogues (3e-m) displayed very good activity (0.10-0.78 
µg/mL), but they were not as effective as 3a-c. The cyclooc-
tyl analogue (3n) displayed excellent activity against Asper-
gillus strains (s0.02-0.05 µg/mL). These values were 
equivalent to analogues 3a-c. 
Example 2 
Time-Kill Assays 
The efficiency of the compounds to kill C. albicans ATCC 
64124 (strain B) was monitored using a previously pub-
lished protocol. The cell suspensions were prepared to 
achieve an inoculum of approximately l-4xl05 CFU/mL in 
RPMI 1640 medium at 35° C. 100 µL of cell suspension was 
added to 900 µL of sterile dd H20 (control) or to sterile dd 
H20 with ebselen, ebsulfur (2a), and 3a at concentrations of 
1 x, 2x, and 4x their respective MIC values. After fungal cell 
addition, at 0, 3, 6, 9, 12, and 24 h, the tubes were vortexed 
and 100 µL aliquots were removed from each solution, 
spread onto PDA plates, and incubated at 35° C. Colony 
Non-aromatic ring analogues (3k-o) were also evaluated. 30 
The cyclopentyl analogue (3k) was found to be just as active 
(0.39-1.56 µg/mL) as analogues 3a-c. The cyclohexyl ana-
logue (31) displayed very good to good activity (0.78-3.13 
µg/mL), but overall was not as active as analogue 3k. The 
cycloheptyl (3m) and cyclooctyl (3n) analogues were also 35 
not as active as analogues 3k, 1. Adamantyl analogue (3o) 
was not soluble in the RPMI 1640 medium that was used for 
determination of MIC values. Thus, the SAR showed a 
modest preference for smaller size ring, as systematically 
expanding the ring size resulted in a gradual loss in activity. 
Ebsulfur 4 Series 
40 counts were determined after 24 h of incubation. The 
experiments were performed in duplicate (FIG. 2). 
Ebsulfur Series 4 
R ~ substituted or unsubstituted alkyl or cycloalkyl 
Lastly, oxidized analogues 4e, 4f, and 4n were tested. It 
was found that oxidizing the sulfur atom to sulfoxide 
completely abolished the antifungal activity of the ana-
logues. This finding was in accord with previous reports of 
these compounds as antibacterials and with other reports in 
the literature that the biological activity of ebselen (1) and 
ebsulfur (2a) was highly dependent on the Se-N or S-N 
bonds. Ngo, H. X. et al. (2016) Development of ebsulfur 
analogues as potent antibacterials against methicillin-resis-
tant Staphylococcus aureus. Bioorg. Med. Chem. doi: 
10.1016/j.bmc.2016.03.060; Lu, J. et al. (2013) Ebsulfur is 
a benzisothiazolone cytocidal inhibitor targeting the try-
panothione reductase of Trypanosoma brucei. J. Biol. Chem. 
288, 27456-27468. Ebselen (1) has been reported to utilize 
Time-kill assays with ebsulfur (2a) and analogue 3a (FIG. 
2) were performed to determine the rate of fungicidal 
activity of the compounds if the invention. The results were 
45 compared to ebselen (1) and the clinically potent and widely 
used antifungal agent AmB, which also served as positive 
control in the time-kill assays. First, all tested compounds 
(ebselen (1), ebsulfur (2a), 3a, and AmB) were dosed at Ix 
their respective MIC values (FIG. 2A). Although the MIC 
50 value for ebsulfur (2a) against strain B was observed to be 
greater than 12.5 µg/mL, ebsulfur (2a) was tested at 12.5 
µg/mL due to concerns that higher concentration may lead to 
precipitation of the compounds. Ebselen (1) (at 12.5 µg/mL) 
displayed potent fungicidal activity leading to complete 
55 fungal cell death at the 6-h mark, which was even quicker 
thanAmB (at 3.9 µg/mL). Ebsulfur (2a) (at 12.5 µg/mL) and 
ebsulfur analogue 3a (at 0.39 µg/mL) displayed fungistatic 
effects. However, at their lx MIC, ebsulfur (2a) and 3a were 
not able to completely inhibit fungal re-growth even after 24 
60 h incubation. Hence, the doses of these compounds were 
doubled in additional time-kill analysis experiments. 
At 2x MIC (FIG. 2B), Ebselen (1) (at 25 µg/mL) and 
AmB (at 7.8 µg/mL) were completely fungicidal from 3 and 
6 h, respectively. At the higher concentration, ebsulfur (2a) 
65 (25 µg/mL) became fungicidal. Compound 3a (at 0.78 
µg/mL) remained fungistatic with a 4-log reduction of 
fungal cells at approximately the 24-h mark. When, the 
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concentration of compound 3a was increased to 4x its MIC 
value (at 1.56 µg/mL), compound 3a remained fungistatic 
(FIG. 2C). These findings suggested that, to be effective 
antifungal agents, ebsulfur (2a) and compound 3a would 
have to be dosed at least 2x their respective MIC values. 5 
However, ebselen (1) could still be effective at lx MIC. 
mechanically removed by cell scrapers (J774A.1 cell line). 
The cells were transferred into 96-well microtiter plates at a 
density of lxl04 cells/mL (HEK-293 cell line) or 2xl04 
cells/mL (J774A.1 cell line) and were grown for 16 h 
overnight. The following day, the media were replaced by 
fresh media (100 µL) containing no compound (negative 
control), triton-X 100® (positive control) (1 %, v/v), and 
serially diluted ebselen (1), 3a, 3b, and 3g at final concen-
trations of 10-0.02 µg/mL. Every well contained 0.1% 
Example 3 
Hemolytic Assays 
Hemolytic activity was determined as previously 
described with minor modifications (FIG. 3). Shrestha, S. K. 
et al. (2015) A combination approach to treating fungal 
infections, Sci. Rep. 5, 17070. Murine red blood cells 
(mRBCs) (1 mL) were suspended in 9 mL of phosphate 
buffer saline (PBS; 10 mM, pH 7.2) and then centrifuged 
(1,200 rpm) for 10 min at room temperature. mRBCs were 
washed with PBS 4 times and then resuspended in fresh PBS 
(5 mL) to achieve the final concentration of (lx107 mRBCs/ 
mL). Compounds were serially diluted in Eppendorf tubes 
containing H20 (100 µL). The mRBC suspension was then 
added to achieve final concentrations ranging from 31.2-
0 .24 µg/mL and 5 x 106 mRBCs/mL of tested compounds and 
mRBCs, respectively. The tubes were then incubated for 1 h 
at 37° C. Tubes containing dd H20 (200 µL) and triton 
X-100® (1% v/v, 2 µt) served as negative (blank) and 
positive (100%) control, respectively. The percent hemolysis 
was calculated using the following equation: % hemolysis= 
[(absorbance of sample)-(absorbance of blank)]xl00/(ab-
sorbance of positive control). Fifty percent hemolysis 
(HC50) values were defined as the concentrations of com-
pounds required to lyse 50% of the mRBCs. 
Previous studies of aminoglycoside analogues reported 
that aminoglycoside analogues with linear alkyl chains 
could be toxic to red blood cells (RBCs) because, due to 
their ultra-thin cell membranes, RBCs are prone to hemoly-
sis. Therefore, analogues with linear alkyl chains, such as 
the C5 analogue 3a and the C8 analogue 3c, were tested 
against murine red blood cells (mRBCs) and compared to 
ebselen (1) (FIG. 3). Most of the tested compounds (ebselen 
(1), ebsulfur (2a), and compound 3c) did not show signifi-
cant hemolytic activity until 15.6 µg/mL. Although com-
pound 3a initially appeared to be hemolytic at approximately 
3.9 µg/mL, this compound exhibited remarkable potency 
against fungal cells. The MIC values of compound 3a were 
at least 5- to 195-fold lower than the hemolytic concentra-
tions for Candida and Aspergillus strains, respectively. 
Thus, some cytocidal selectivity towards fungal cells was 
observed. 
Example 4 
Mammalian Cytotoxicity Assay 
Compounds 3a, 3b, and 3g (in terms of their overall 
antifungal activity against both Candida and Aspergillus 
strains) were evaluated against two different mammalian cell 
lines, which have normal cell membranes and are not 
susceptible to membrane-lytic compounds. 
10 DMSO, which is not toxic against these manimalian cell 
lines. The cells were incubated with tested compounds for 
another 24 h at 37° C. with 5% CO2 . Cell survival was 
assessed by resazurin assay. Each well was treated with 
resazurin (10 µL of a 25 mg/L solution) for 6 h. Live cells 
15 produced the highly fluorescent pink dye resorufin, which 
was detected at A560 absorption and A590 emission by a 
SpectraMax MS plate reader. Dead cells remain purple/blue. 
The percentage of survival rate was calculated by using the 
following formula: [(test value)/(control value)xl00]. The 
20 control value is obtained from the wells, which have cells 
and resazurin, but no tested compounds. 
ROS production assay was performed as previously 
described with minor modifications. The 2',7'-dichlorodihy-
drofluorescein diacetate (DCFH-DA) probe was used to 
25 measure the production of ROS in fungal cells after treat-
ment of cells with ebselen, ebsulfur (2a), and 3a. Once 
entering the cells, the DCFH-DA probe is first hydrolyzed to 
the non-fluorescent 2',7'-dichlorodihydrofluorescein 
(DCFH) by cellular esterases. After that, DCFH is oxidized 
30 to the highly fluorescent 2',7'-dichlorofluorescein (DCF) by 
intracellular ROS. A colony of C. albicans ATCC 10231 
(strain A) was used to inoculate 5 mL of PDB in a Falcon 
tube and grown overnight at 35° C. at 200 rpm. In the 
morning, the culture was diluted by addition of fungal cells 
35 (200 µL) to RPMI 1640 medium (800 After that, newly 
diluted cell suspension (100 µL) was added to the RPMI 
1640 medium (900 µL) containing no drug (negative con-
trol) or ebselen, 2a, and 3a, at their lx and 2x MIC values 
and incubated for 1 hat 37° C. Glass slides (with 10-15 of 
40 each mixture) were prepared and observed in bright field and 
fluorescence modes (FITC filter set, "-ex =488 nm and 
"-em =512 nm excitation) using a Zeiss Axovert 200M fluo-
rescence microscope (FIG. 5). 
Compounds 3a, 3b, and 3g were evaluated for their 
45 cytotoxicity against HEK293 and 1774 cell lines using a 
resazurin assay. The percentage of surviving cells treated 
with the analogues versus the percentage of surviving cells 
treated was compared with ebselen (1) (FIG. 4). Against the 
HEK293 cell line (FIG. 4A), the analogues (3a, 3b, and 3g) 
50 were observed to be slightly more toxic but overall, quite 
comparable to ebselen (1) at all concentrations tested. Over-
all, all the tested compounds (ebselen (1), 3a, 3b, and 3g) 
induced approximately 50 to 40% cell death at 10 µg/mL 
(FIG. 4A). The similarity of cytotoxicity data of ebselen (1) 
55 found in the present study to other reported in vitro mam-
malian cytotoxicity studies of ebselen (1) was verified. 
Given the good tolerability of ebselen (1) during clinical 
trials, it was intriguing to us that compounds 3a and 3b 
displayed similar in vitro cytotoxicity. The HEK293 cell line 
60 was chosen to determine the potential for kidney injury. The 
kidney is a highly perfused organ and comes in contact with 
many compounds due to renal excretion. Thus, many com-
pounds such as AmB are highly nephrotoxic and cause great 
Manimalian cytotoxicity assays were performed as pre-
viously described with minor modifications (FIG. 4). The 
HEK-293 and J774A.1 cell lines were grown in various 
Dulbecco's Modified Eagle's Medium (DMEM) with 10% 
fetal bovine serum (FBS) and 1 % Pen/Strep at 37° C. with 65 
5% CO2 . The confluent cells were either trypsinized with 
0.05%-trypsin-0.53 mM EDTA (HEK-293 cell line) or 
burden to patients with compromised renal function. 
Next, the compounds were evaluated against 1774 (FIG. 
4B), a murine macrophage cell line. This cell line was 
selected to test that the compounds would not interfere with 
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the survival of host macrophages, because macrophages are 
the first-line of defense against fungal infection. Against the 
1774 cell line, a trend similar to the HEK293 cell line was 
observed. It was found that analogues (3a and 3b) were 
slightly more toxic but still comparable to ebselen (1) with 5 
approximately 50% cell death at 10 µg/mL. Compounds 3g 
did not show any toxicity up to 5 µg/mL. 
48 
to be highly fluorescent, indicating ROS induction. Samples 
that were treated with different doses of compounds (lx and 
2x their respective MIC values) were also compared, and it 
was observed that the amount ROS induction could be 
concentration dependent. It is unclear, however, whether this 
ROS induction in C. albicans spp. is due to inhibition of a 
specific fungal enzyme responsible for ROS regulation or it 
is a downstream secondary effect as the ebselen (1) and 
ebsulfur (2a) scaffolds inhibit enzymes that are unrelated to Example 5 
ROS Production 
10 ROS generation. 
Although there are concerns in the literature regarding the 
highly reactive isothiazolinone moiety of the ebsulfur (2a) 
scaffold, the scaffold merits further consideration and opti- 15 
mization as a possible antifungal candidate based on two 
particular reasons. First, since many potent antifungal com-
pounds are only available intravenously ( e.g., polyenes and 
echinocandins), there is currently a dire clinical need for 
orally active antifungals to assist the azoles as an alternative 20 
option for step-down therapy. As of 2016, the IDSA clinical 
practice guideline recommends the use of step-down thera-
pies for many invasive fungal diseases. These azoles, how-
ever, often complicate drug dosing and require many dose 
adjustments for numerous immunocompromised patients 25 
due to interactions with the metabolism of anticancer and 
Example 6 
Pharmacokinetic and Pharmacodynamic Studies 
Maximum Tolerated Dose Studies. Maximum tolerated 
dose studies are conducted. Three "low", "medium", and 
"high" doses of compounds of formula (I) are selected based 
on previous ebselen animal studies. The low dose is 15 
mg/kg, the medium dose is 30 mg/kg, and the high dose is 
45 mg/kg (Ozyigit et al. 2015). The ebsulfur analogues are 
dissolved in 1 mL of 10% Tween 80 (Sigma-Aldrich, St. 
Louis, Mo., USA). Healthy outbred CD-1 (Charles River, 
the Netherlands) female mice from 4 to 5 weeks old, 
weighing between 20 to 25 g, are randomized to 4 treatment 
groups of sham, low, medium, and high dose treatment. 
Each group contains three mice. On the day of treatment, 
mice in each treatment group receive the appropriate intra-
venous (IV) doses of vehicle, low, medium, and high dose. 
30 Body changes and other signs of toxicity of the treated mice 
are monitored over a period of 2 weeks. Common signs of 
toxicity include weight loss, shakiness, distress, etc. Mice 
observed losing more than 15% body weight are euthanized. 
The maximum tolerated dose is determined as the dose that 
antiretroviral drugs. Additionally, some pathogenic fungal 
strains are increasingly resistant to FLC, the most popular 
azole, especially in patients who experience previous FLC 
administration. Ebselen was successfully administered 
orally during both phase 1 and 3 clinical trials. Due to its 
structural similarity to ebselen (1), the ebsulfur (2a) scaffold 
would most likely be orally active and potentially be a 
highly valuable addition to the current step-down therapy. 
Second, while there are concerns about the high reactivity of 35 
the isothiazolinone moiety towards cysteine residues, 
ebselen (1) with the isoselenazolinone moiety has been 
shown to be well-tolerated during clinical trials. Addition-
ally, there are also examples of other clinically successful 
small-molecule inhibitors with highly reactive chemical 40 
moieties within the FDA-approved chemical space. Some of 
these compounds are penicillin, fosfomycin, or bendamus-
tine. As in many cases, it is often the dose that determines 
the poison. 
Compounds 3a and 3b displayed MIC values against 45 
clinically relevant Candida strains at 780 ng/mL and Asper-
gillus strains at s20 ng/mL. This difference in fungal and 
mammalian toxic concentrations could be due to the stron-
ger binding affinity that compounds 3a and 3b have for 
fungal target(s) compared to the binding affinity that they 50 
have for mammalian targets. Thus, ROS induction of ebsul-
fur analogues was studied to understand the mechanism of 
action of these compounds. 
Recently, it was shown that ebselen (1) and the ebsulfur 
analogues with antibacterial activity were highly correlated 55 
with ROS production in MRSA bacterial cells. It was also 
reported that ebselen (1) induced ROS-mediated cytotoxic-
ity in Saccharomyces cerevisiae. Thus, whether the com-
pounds of the invention would also induce ROS against C. 
albicans was studied. Ebselen (1), ebsulfur (2a), and com- 60 
pound 3a were tested against C. albicans ATCC 10231 cells 
(strain A) at lx and 2x their respective MIC values. 2',7'-
dichlorodihydrofluorescin diacetate (DCFH-DA) was then 
used to detect and visualize ROS production (FIG. 5). As a 
positive control, cells were treated with H2 0 2 , which is an 65 
inducer of hydroxyl radical formation. After 1-h treatment, 
all the compounds tested and the positive control were found 
causes unacceptable side effects or signs of toxicity. 
Bioanalytical Method Development. Next, bioanalytical 
methods are developed and the lower limit of detection dose 
is determined for the selected compounds of formula (I) 
using reversed-phase high-performance liquid chromatogra-
phy (HPLC). Masses of the compounds are confirmed by 
Q-TOF Tandem Mass Spectrometer. 
Pharmacokinetic Studies. Doses chosen for pharmacoki-
netics studies are determined by the lower limit of detection 
dose and the maximum tolerated doses. Healthy outbred 
CD-1 female mice from 4 to 5 weeks old, weighing between 
20 to 25 g are used. For each dose, mice are randomly 
divided into 2 h, 4 h, 8 h, 12 h, and 24 h treatment groups. 
There are three mice for each time point. At each time point, 
the blood sample is collected to determine plasma drug 
concentration by saphenous vein bleed (50 µL of whole 
blood). Geometric mean concentrations of total drug in 
plasma are calculated for each time point. Pharmacokinetic 
parameters are derived using noncompartmental analysis. 
Distribution Studies. Next, the extent of distribution of 
compounds of formula (I) into certain tissues such as liver, 
lung, heart, or kidney is determined. Experimental condi-
tions used in the pharmacokinetic studies are repeated. 
Mouse organs are collected, tissue extractions are per-
formed, and the previously determined bioanalytical method 
to quantify drug concentrations is used to compare com-
pound concentrations in organs to compound concentrations 
in the plasma. Of particular interest is the study of com-
pound concentration in the lungs with respect to pulmonary 
Aspergillosis infections. 
Pharmacodynamic Studies. Doses of compounds of for-
mula (I) are selected to perform pharmacodynamics (PD) 
experiment to understand whether the compounds are effec-
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tive in clearing Candida spp. and Aspergillus spp. in vivo. 
Clinical C. albicans, C. glabrata, and A. fumigatus isolates 
are obtained from patients at University of Kentucky Medi-
cal Center. An infection model for pharmacodynamic studies 
reported by Seyedmousavi et al. 2014 is used. CD-1 female 5 
mice, 4 to 5 weeks old, weighing 20 to 25 g are randomized 
into three treatment groups: placebo, ebsulfur analogue, and 
itraconazole with three mice per group. In order to infect the 
mice, the mice are first treated with cyclophosphamide (150 
mg/kg on days -4 and +4, and 100 mg/kg on day -1). On 10 
day O and 2 h after drug treatments, mice are infected with 
C. albicans, C. glabrata, A.fumigatus isolates. For the blood 
infection models of C. albicans and C. glabrata, mice are 
given inoculum iv. For the special pulmonary Aspergillosis 15 
mouse model, mice are infected via instillation of the 
inoculum through the animals' nares using a well-estab-
lished procedure in the literature. The inoculum size is 
determined to be corresponding to the LD90 (lethal dose, 
90%) of the mice. The infected mice are treated with the 20 
appropriate treatments based on their assigned groups. Sur-
vival in days post-infection are recorded for each mouse in 
each group. Clinical toxicity effects are monitored. Mice 
demonstrating acute signs of disease are humanely eutha-
nized. On day 15 post-infection, all surviving mice are 25 
euthanized. 
Topical Treatment Studies. Eight-week old female 
BALB/c mice are used for topical treatment studies (Harlan 
Laboratories, Indianapolis, Ind.) (Thangamani et al. 2015). 
Mice are injected intradermally with an inoculum of a 30 
dermatophyte fungal strain. After 48 h, the site of infection 
develops into an open wound. The mice are randomized into 
50 
Leaf Infection Assay. The published protocol by Chang et 
al. (2010) is followed to perform leaf and wheat head 
spikelets infection assays. Rapidly maturing wheat cultivar 
Apogee (Bugbee et al. 1997) is used for this experiment. The 
phytotoxic effect of compounds of formula (I) are evaluated 
by applying the compounds on the leaf of wheat plant. To 
achieve this, various concentrations of compounds of for-
mula (I) at 2xMIC, 6xMIC and 20xMIC are prepared in 
0.25% (w/v) agar and 0.2% (v/v) Tween® 20 solution and on 
leaf. Next, F. graminearum spores are mixed at the final 
concentration of lxl04 macroconidia/mL along with the 
compounds of formula (I) at each concentration. Finally, the 
phytotoxic effect of the compounds of formula (I) on wheat 
plant and the development of infection by F. graminearum 
is assessed. Development of leaf lesion and chlorosis is 
monitored to analyze either the phytotoxic effect or the 
establishment of infection by F. graminearum in wheat. 
Wheat Head Spikelets Infection Assay. The published 
protocol by Chang et al. (2010) is followed to perform wheat 
head spikelets infection assay. Rapidly maturing wheat 
cultivar Apogee (Bugbee et al. 1997) is used for this 
experiment. Wheat cultivar Apogee is grown for 5-6 weeks 
in a greenhouse to the flowering stage. The florets ( one per 
spikelet) are first treated with various concentrations of 
compounds of formula (I) at 2xMIC, 6xMIC and 20xMIC 
and then are inoculated by F. graminearum macroconidia. 
The development of disease symptoms such as chlorosis, 
spikelet curling and dehydration is recorded after 4 days. 
The foregoing description and examples have been set 
forth merely to illustrate the invention and are not meant to 
be limiting. Since modifications of the described embodi-
ments incorporating the spirit and the substance of the 
invention may occur to persons skilled in the art, the 
invention should be construed broadly to include all varia-
tions within the scope of the claims and equivalents thereof. 
The invention claimed is: 
5 groups of 3 mice in each. One group receives petroleum 
jelly alone. Three groups receive 0.5%, 1 %, and 2% ebsulfur 
analogue in petroleum jelly. The fifth group receives the 35 
FDA-approved drug Lamisil or terbinafine product. All 
groups are treated twice a day for 5 days. After the last 
treatment, recovery of each group is monitored. 1. A method of treating an infection caused by a fungal 
species, comprising administering to a subject in need 
40 thereof a therapeutically effective amount of a compound of 
formula (I): Example 7 
Agricultural Studies 
Honeybee toxicity. The published methods by the U.S. 
Environmental Protection Agency (EPA) Office of Preven- 45 
tion, Pesticides, and Toxic Substances (OPPTS) are fol-
lowed with minor modifications (EPA, US 1996). As rec-
ommended by the OPPTS, Apis mellifera species is used. 
Worker honeybees are seized at the entrance of a single 
healthy hive the day of use. The bees are brought to the 50 
laboratory and kept in a small cage at room temperature. 
Honey bees are first anesthetized with CO2 before use and 
transferred to three individual cups having total of 10 bees 
in each cup. To evaluate the toxicity effect of ebsulfur 
compounds against honeybees, acute oral and acute contact 55 
tests are performed. To perform acute oral toxicity, honey-
bees are fed with 200 µL of different concentrations of 
ebsulfur compounds. Likewise, to perform acute contact 
test, honeybees are anesthetized again with CO2 and differ-
ent concentrations of ebsulfur compounds are applied in 1 60 
µL drops to the ventral side of the thorax of each bee. After 
treatments, the bees are fed with 3 mL of sucrose solution 
(50% volume of sucrose and 50% volume of water). The 
cups are stored at 28° C. incubator for 48 hand are checked 
every 4 h. The ratio of living to dead bees is recorded. The 65 
treatments with each concentration are replicated at least 
thrice. 
R, ~N-R l __ Jl> 
wherein 
X is Se, S, or S=O; 
Y is C, N, or O; 
y X 
(I) 
R is substituted or unsubstituted aryl, substituted or 
unsubstituted heteroaryl, substituted or unsubstituted 
alkyl, substituted or unsubstituted cycloalkyl, or ORa; 
R1 is -H, --OH, -NH2 , OR6 , CF3 , NO2 , or CN; 
Ra is linear or branched C1_16 alkyl groups or linear 
pegylated C4 . 16 alkyl groups; and 
R6 is linear or branched C1. 16 alkyl groups; 
or a salt thereof. 
2. A method as in claim 1, wherein Xis Se; R is phenyl; 
or a salt thereof. 
3. A method as in claim 1, wherein Xis S; R is substituted 
or unsubstituted aryl, substituted or unsubstituted heteroaryl, 
substituted or unsubstituted alkyl, or substituted or unsub-
stituted cycloalkyl; or a salt thereof. 
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4. A method as in claim 1, wherein X is S=O; R is 
substituted or unsubstituted aryl, substituted or unsubstituted 
heteroaryl, substituted or unsubstituted alkyl, or substituted 
or unsubstituted cycloalkyl; or a salt thereof. 
5. A method as in claim 1, wherein the fungal species is 5 
selected from the group consisting of Candida, Aspergillus, 
Trichophyton, Fusarium, Microsporum, Blumeria, 
Podosphaera, Sphaerotheca, Phakopsora, Puccinia, Uro-
myces, Peronospora, Phytophthora, Plasmopara, Pythium, 
Alternaria, Cercospora, Cladiosporium, Colletotrichum, 10 
Cycloconium, Cochhobolus, Gloeosporium, Glomerella, 
Guignardia, Leptosphaeria, Magnaporthe, Botrytis, Peni-
cillium, Sclerotinia, Verticillium, Rhizoctonia, Sclerotium, 
Nectria, Monilinia, and Helminthosporium species. 
6. A method as in claim 5, wherein the Candida species 15 
is selected from the group consisting of Candida albicans, 
Candida glabrata, Candida krusei, or Candida parapsilosis. 
7. A method as in claim 5, wherein theAspergillus species 
is selected from the group consisting of Aspergillus flavus, 
Aspergillus nidulans, and Aspergillus terreus. 20 
8. A method as in claim 1, wherein the subject is a 
mammal. 
9. A method as in claim 1, wherein the subject 1s an 
agricultural crop. 
* * * * * 
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